BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-järvinen H, Grønbæk H, Cortez-pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome PN, Anstee QM, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin SK, Harrison S, Kawaguchi T, Wong VW, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;158:1999-2014.e1. [DOI: 10.1053/j.gastro.2019.11.312] [Cited by in Crossref: 428] [Cited by in F6Publishing: 423] [Article Influence: 214.0] [Reference Citation Analysis]
Number Citing Articles
1 Alharthi J, Eslam M. Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease. Hepatobiliary Surg Nutr 2021;10:696-8. [PMID: 34760977 DOI: 10.21037/hbsn-21-269] [Reference Citation Analysis]
2 Licata A, Zerbo M, Como S, Cammilleri M, Soresi M, Montalto G, Giannitrapani L. The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement? Nutrients 2021;13:4014. [PMID: 34836267 DOI: 10.3390/nu13114014] [Reference Citation Analysis]
3 Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2021. [PMID: 34472683 DOI: 10.1111/hepr.13706] [Reference Citation Analysis]
4 Santos-Baez LS, Ginsberg HN. Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Curr Opin Lipidol 2021;32:200-6. [PMID: 33883445 DOI: 10.1097/MOL.0000000000000756] [Reference Citation Analysis]
5 Ohtani N, Hara E. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota. Cancer Sci 2021. [PMID: 34533882 DOI: 10.1111/cas.15142] [Reference Citation Analysis]
6 Li X, Wang H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci 2020;10:140. [PMID: 33372630 DOI: 10.1186/s13578-020-00507-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mantovani A. MAFLD vs NAFLD: Where are we? Dig Liver Dis 2021;53:1368-72. [PMID: 34108096 DOI: 10.1016/j.dld.2021.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
9 Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;. [PMID: 32997882 DOI: 10.1111/liv.14675] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 46.0] [Reference Citation Analysis]
10 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
11 Azhie A, Sheth P, Hammad A, Woo M, Bhat M. Metabolic Complications in Liver Transplantation Recipients: How We Can Optimize Long-Term Survival. Liver Transpl 2021. [PMID: 34165872 DOI: 10.1002/lt.26219] [Reference Citation Analysis]
12 Serrano-Maciá M, Simón J, González-Rellan MJ, Azkargorta M, Goikoetxea-Usandizaga N, Lopitz-Otsoa F, De Urturi DS, Rodríguez-Agudo R, Lachiondo-Ortega S, Mercado-Gomez M, Gutiérrez de Juan V, Bizkarguenaga M, Fernández-Ramos D, Buque X, Baselli GA, Valenti LVC, Iruzubieta P, Crespo J, Villa E, Banales JM, Avila MA, Marin JJG, Aspichueta P, Sutherland J, Barrio R, Mayor U, Elortza F, Xirodimas DP, Nogueiras R, Delgado TC, Martínez-Chantar ML. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Mol Metab 2021;53:101275. [PMID: 34153521 DOI: 10.1016/j.molmet.2021.101275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Kragh Petersen S, Bilkei-Gorzo O, Govaere O, Härtlova A. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD). Scand J Immunol 2020;92:e12971. [PMID: 32892401 DOI: 10.1111/sji.12971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
14 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gough A, Soto-Gutierrez A, Vernetti L, Ebrahimkhani MR, Stern AM, Taylor DL. Human biomimetic liver microphysiology systems in drug development and precision medicine. Nat Rev Gastroenterol Hepatol 2021;18:252-68. [PMID: 33335282 DOI: 10.1038/s41575-020-00386-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Zakaria Z, Othman ZA, Suleiman JB, Che Jalil NA, Ghazali WSW, Nna VU, Mohamed M. Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation. Antioxidants (Basel) 2021;10:2031. [PMID: 34943134 DOI: 10.3390/antiox10122031] [Reference Citation Analysis]
17 Li N, Xie G, Zhou B, Qu A, Meng H, Liu J, Wang G. Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease. Front Physiol 2021;12:696163. [PMID: 34366886 DOI: 10.3389/fphys.2021.696163] [Reference Citation Analysis]
18 MacDonald-Ramos K, Michán L, Martínez-Ibarra A, Cerbón M. Silymarin is an ally against insulin resistance: A review. Ann Hepatol 2021;23:100255. [PMID: 32950646 DOI: 10.1016/j.aohep.2020.08.072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. Front Med (Lausanne) 2021;8:693507. [PMID: 34277667 DOI: 10.3389/fmed.2021.693507] [Reference Citation Analysis]
20 Gao F, Zheng KI, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, Targher G, Byrne CD, George J, Zheng MH. Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Front Endocrinol (Lausanne) 2021;12:604100. [PMID: 33763027 DOI: 10.3389/fendo.2021.604100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Liu Q, Cai BY, Zhu LX, Xin X, Wang X, An ZM, Li S, Hu YY, Feng Q. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice. Life Sci 2020;261:118457. [PMID: 32961235 DOI: 10.1016/j.lfs.2020.118457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Cheng YM, Kao JH, Wang CC. The metabolic profiles and body composition of lean metabolic associated fatty liver disease. Hepatol Int 2021;15:405-12. [PMID: 33539004 DOI: 10.1007/s12072-021-10147-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Liu K, Qiu D, Liang X, Huang Y, Wang Y, Jia X, Li K, Zhao J, Du C, Qiu X, Cui J, Xiao Z, Qin Y, Zhang Q. Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy. Autophagy 2021;:1-17. [PMID: 34382907 DOI: 10.1080/15548627.2021.1961072] [Reference Citation Analysis]
25 Zhang X, Li R, Chen Y, Dai Y, Chen L, Qin L, Cheng X, Lu Y. The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor. Front Endocrinol (Lausanne) 2020;11:598836. [PMID: 33363517 DOI: 10.3389/fendo.2020.598836] [Reference Citation Analysis]
26 Hoene M, Kappler L, Kollipara L, Hu C, Irmler M, Bleher D, Hoffmann C, Beckers J, Hrabě de Angelis M, Häring HU, Birkenfeld AL, Peter A, Sickmann A, Xu G, Lehmann R, Weigert C. Exercise prevents fatty liver by modifying the compensatory response of mitochondrial metabolism to excess substrate availability. Mol Metab 2021;:101359. [PMID: 34695608 DOI: 10.1016/j.molmet.2021.101359] [Reference Citation Analysis]
27 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Reference Citation Analysis]
28 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
29 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
30 Eng JM, Estall JL. Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol. Cells 2021;10:1805. [PMID: 34359974 DOI: 10.3390/cells10071805] [Reference Citation Analysis]
31 Beier JI, Arteel GE. Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns. Acta Pharmaceutica Sinica B 2021;11:3768-78. [DOI: 10.1016/j.apsb.2021.09.005] [Reference Citation Analysis]
32 Kuchay MS, Misra A. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years. Diabetes Metab Syndr 2020;14:695-6. [PMID: 32442920 DOI: 10.1016/j.dsx.2020.05.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
33 Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol 2021;74:972-4. [PMID: 33340575 DOI: 10.1016/j.jhep.2020.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Lee JH, Lee HS, Ahn SB, Kwon YJ. Dairy protein intake is inversely related to development of non-alcoholic fatty liver disease. Clin Nutr 2021;40:5252-60. [PMID: 34534894 DOI: 10.1016/j.clnu.2021.08.012] [Reference Citation Analysis]
35 Pastore A, Panera N, Mosca A, Caccamo R, Camanni D, Crudele A, De Stefanis C, Alterio A, Di Giovamberardino G, De Vito R, Francalanci P, Battaglia S, Muda AO, De Peppo F, Alisi A. Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. Obes Surg 2021. [PMID: 34546515 DOI: 10.1007/s11695-021-05701-6] [Reference Citation Analysis]
36 Licata A, Minissale MG, Distefano M, Montalto G. Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? GastroHep 2021;3:121-30. [PMID: 34149320 DOI: 10.1002/ygh2.455] [Reference Citation Analysis]
37 Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Ronda OAHO, Verkade HJ, Stojakovic T, Scharnagl H, Trauner M. Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. Int J Mol Sci 2021;22:2126. [PMID: 33672787 DOI: 10.3390/ijms22042126] [Reference Citation Analysis]
38 Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel) 2020;10:E940. [PMID: 33198092 DOI: 10.3390/diagnostics10110940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
39 Roberts SK, Majeed A, Glenister K, Magliano D, Lubel JS, Bourke L, Simmons D, Kemp WW. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. Med J Aust 2021;215:77-82. [PMID: 34028830 DOI: 10.5694/mja2.51096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Li YM, Zhao SY, Zhao HH, Wang BH, Li SM. Procyanidin B2 Alleviates Palmitic Acid-Induced Injury in HepG2 Cells via Endoplasmic Reticulum Stress Pathway. Evid Based Complement Alternat Med 2021;2021:8920757. [PMID: 34956386 DOI: 10.1155/2021/8920757] [Reference Citation Analysis]
41 Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Dig Liver Dis. 2021;53:153-157. [PMID: 33011088 DOI: 10.1016/j.dld.2020.09.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
42 Chen Z, Liu J, Zhou F, Li H, Zhang XJ, She ZG, Lu Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circ Res 2021;128:1747-65. [PMID: 34043417 DOI: 10.1161/CIRCRESAHA.121.319059] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhou YJ, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol. 2020;73:719-721. [PMID: 32348790 DOI: 10.1016/j.jhep.2020.04.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 25.5] [Reference Citation Analysis]
44 Liu J, Mu C, Li K, Luo H, Liu Y, Li Z. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis. Int J Public Health 2021;66:1604371. [PMID: 34690666 DOI: 10.3389/ijph.2021.1604371] [Reference Citation Analysis]
45 Fiorucci S, Distrutti E. Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med 2022;28:51-66. [PMID: 34815180 DOI: 10.1016/j.molmed.2021.10.005] [Reference Citation Analysis]
46 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
47 Osborne N, Leahy C, Lee YK, Rote P, Song BJ, Hardwick JP. CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD). Biochem Pharmacol 2021;:114841. [PMID: 34798124 DOI: 10.1016/j.bcp.2021.114841] [Reference Citation Analysis]
48 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Reference Citation Analysis]
49 Cordeiro A, Ribamar A, Ramalho A. ADIPOSE TISSUE DYSFUNCTION AND MAFLD IN OBESITY ON THE SCENE OF COVID-19. Clin Res Hepatol Gastroenterol 2021;:101807. [PMID: 34543756 DOI: 10.1016/j.clinre.2021.101807] [Reference Citation Analysis]
50 Chen B, Huang H, Pan CQ. The role of gut microbiota in hepatitis B disease progression and treatment. J Viral Hepat 2021. [PMID: 34415656 DOI: 10.1111/jvh.13595] [Reference Citation Analysis]
51 Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med 2021;11:684. [PMID: 34442328 DOI: 10.3390/jpm11080684] [Reference Citation Analysis]
52 Liu Z, Wang J, Chen S, Xu C, Zhang Y. Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study. Environ Health 2021;20:98. [PMID: 34461916 DOI: 10.1186/s12940-021-00783-2] [Reference Citation Analysis]
53 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Elfeki MA, Robles J, Akhtar Z, Ullah F, Ganapathiraju I, Tran C, Inman C, Collin SM, Rosa R. Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 34173917 DOI: 10.1007/s10620-021-07120-0] [Reference Citation Analysis]
55 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
56 Liu S, Wang J, Wu S, Niu J, Zheng R, Bie L, Xin Z, Wang S, Lin H, Zhao Z, Wang T, Xu M, Lu J, Chen Y, Xu Y, Wang W, Ning G, Bi Y, Li M, Xu Y. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. Metabolism 2021;120:154779. [PMID: 33895182 DOI: 10.1016/j.metabol.2021.154779] [Reference Citation Analysis]
57 Xu X, Nan Y. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease". J Hepatol 2021:S0168-8278(21)02170-X. [PMID: 34774637 DOI: 10.1016/j.jhep.2021.11.003] [Reference Citation Analysis]
58 Dallio M, Romeo M, Gravina AG, Masarone M, Larussa T, Abenavoli L, Persico M, Loguercio C, Federico A. Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. Nutrients 2021;13:1679. [PMID: 34063372 DOI: 10.3390/nu13051679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World J Diabetes 2021; 12(9): 1576-1586 [PMID: 34630909 DOI: 10.4239/wjd.v12.i9.1576] [Reference Citation Analysis]
60 Kamimura H, Kimura A, Terai S. Potential Effect of a Selective Peroxisome Proliferator-activated Receptor Alpha Modulator on Metabolic Dysfunction-associated Fatty Liver Disease. Intern Med 2021;60:2165-6. [PMID: 33612688 DOI: 10.2169/internalmedicine.6906-20] [Reference Citation Analysis]
61 van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology 2021. [PMID: 34453359 DOI: 10.1002/hep.32131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Lai S, Li J, Wang Z, Wang W, Guan H. Sensitivity to Thyroid Hormone Indices Are Closely Associated With NAFLD. Front Endocrinol (Lausanne) 2021;12:766419. [PMID: 34803928 DOI: 10.3389/fendo.2021.766419] [Reference Citation Analysis]
63 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
64 Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Högström S, Richardson B, Munoz C, Sigurðardóttir S, Coulibaly A, Milan M, Bautista F, Leung NWY, Mooney V, Obekpa S, Bech E, Polavarapu N, Hamed AE, Radiani T, Purwanto E, Bright B, Ali M, Dovia CK, McColaugh L, Koulla Y, Dufour JF, Soliman R, Eslam M. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 2021;6:73-9. [PMID: 33031758 DOI: 10.1016/S2468-1253(20)30294-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 18.5] [Reference Citation Analysis]
65 Misiakiewicz-Has K, Maciejewska-Markiewicz D, Rzeszotek S, Pilutin A, Kolasa A, Szumilas P, Stachowska E, Wiszniewska B. The Obscure Effect of Tribulus terrestris Saponins Plus Inulin on Liver Morphology, Liver Fatty Acids, Plasma Glucose, and Lipid Profile in SD Rats with and without Induced Type 2 Diabetes Mellitus. Int J Mol Sci 2021;22:8680. [PMID: 34445384 DOI: 10.3390/ijms22168680] [Reference Citation Analysis]
66 Xin X, Jin Y, Wang X, Cai B, An Z, Hu YY, Feng Q. A Combination of Geniposide and Chlorogenic Acid Combination Ameliorates Nonalcoholic Steatohepatitis in Mice by Inhibiting Kupffer Cell Activation. Biomed Res Int 2021;2021:6615881. [PMID: 34095305 DOI: 10.1155/2021/6615881] [Reference Citation Analysis]
67 Mushtaq K, Khan MU, Iqbal F, Alsoub DH, Chaudhry HS, Ata F, Iqbal P, Elfert K, Balaraju G, Almaslamani M, Al-Ejji K, AlKaabi S, Kamel YM. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. J Hepatol 2021;74:482-4. [PMID: 33223215 DOI: 10.1016/j.jhep.2020.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
68 Weng Z, Ou W, Huang J, Singh M, Wang M, Zhu Y, Kumar R, Lin S. Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study. Nat Sci Sleep 2021;13:103-11. [PMID: 33542668 DOI: 10.2147/NSS.S290465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Luci C, Vieira E, Bourinet M, Rousseau D, Bonnafous S, Patouraux S, Lefevre L, Larbret F, Prod'homme V, Iannelli A, Tran A, Anty R, Bailly-Maitre B, Deckert M, Gual P. SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2021;13:173-91. [PMID: 34411785 DOI: 10.1016/j.jcmgh.2021.08.004] [Reference Citation Analysis]
70 Buzova D, Maugeri A, Liguori A, Napodano C, Lo Re O, Oben J, Alisi A, Gasbarrini A, Grieco A, Cerveny J, Miele L, Vinciguerra M. Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clin Epigenetics 2020;12:126. [PMID: 32819448 DOI: 10.1186/s13148-020-00917-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
71 Li M, Rajani C, Zheng X, Jia W. The microbial metabolome in metabolic‐associated fatty liver disease. Journal of Gastroenterology and Hepatology. [DOI: 10.1111/jgh.15746] [Reference Citation Analysis]
72 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Liu Y, Wang S, Hu L. Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients With Chronic Hepatitis B. Hepatology 2021;74:1134-5. [PMID: 33830529 DOI: 10.1002/hep.31842] [Reference Citation Analysis]
74 Valentini D, Mosca A, Di Camillo C, Crudele A, Sartorelli MR, Scoppola V, Tarani L, Villani A, Raponi M, Novelli A, Alisi A. PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome. Nutr Metab Cardiovasc Dis 2020;30:1564-72. [PMID: 32636123 DOI: 10.1016/j.numecd.2020.05.012] [Reference Citation Analysis]
75 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
76 Hundertmark J, Tacke F. How effective are nonalcoholic fatty liver disease models for drug discovery? Expert Opin Drug Discov 2020;15:1237-40. [PMID: 32524859 DOI: 10.1080/17460441.2020.1776258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. Biomedicines 2021;9:1890. [PMID: 34944706 DOI: 10.3390/biomedicines9121890] [Reference Citation Analysis]
78 Xu F, Guo W. The progress of epigenetics in the development and progression of non-alcoholic fatty liver disease. Liver Research 2020;4:118-23. [DOI: 10.1016/j.livres.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Hadefi A, Verset L, Pezzullo M, Rosewick N, Degré D, Gustot T, Moreno C, Devière J, Trépo E. Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. Endosc Int Open 2021;9:E1792-800. [PMID: 34790547 DOI: 10.1055/a-1550-7668] [Reference Citation Analysis]
80 Im YR, Hunter H, de Gracia Hahn D, Duret A, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD. Hepatology 2021. [PMID: 33973269 DOI: 10.1002/hep.31897] [Reference Citation Analysis]
81 Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines 2021;9:1639. [PMID: 34829868 DOI: 10.3390/biomedicines9111639] [Reference Citation Analysis]
82 Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00183-7. [PMID: 34364544 DOI: 10.1016/S2468-1253(21)00183-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
84 Wu Y, Kumar R, Huang J, Wang M, Zhu Y, Lin S. FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD). J Hepatol 2021;74:247-8. [PMID: 32994079 DOI: 10.1016/j.jhep.2020.06.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
85 Valencia-Rodríguez A, Vera-Barajas A, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N. Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease. Ann Hepatol 2020;19:227-9. [PMID: 32359519 DOI: 10.1016/j.aohep.2020.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
86 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
87 Guo T, Gupta A, Yu J, Granados JZ, Gandhi AY, Evers BM, Iyengar P, Infante RE. LIFR-α-dependent adipocyte signaling in obesity limits adipose expansion contributing to fatty liver disease. iScience 2021;24:102227. [PMID: 33748712 DOI: 10.1016/j.isci.2021.102227] [Reference Citation Analysis]
88 Ferrusquía-acosta J, Bassegoda O, Turco L, Reverter E, Pellone M, Bianchini M, Pérez-campuzano V, Ripoll E, García-criado Á, Graupera I, García-pagán JC, Schepis F, Senzolo M, Hernández-gea V. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. Journal of Hepatology 2021;74:811-8. [DOI: 10.1016/j.jhep.2020.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
89 Liu WY, Eslam M, Zheng KI, Ma HL, Rios RS, Lv MZ, Li G, Tang LJ, Zhu PW, Wang XD, Byrne CD, Targher G, George J, Zheng MH. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:194-202. [PMID: 34007801 DOI: 10.14218/JCTH.2020.00151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
91 Dongiovanni P, Meroni M, Petta S, Longo M, Alisi A, Soardo G, Valenti L, Miele L, Grimaudo S, Pennisi G, Antonio G, Consonni D, Fargion S, Fracanzani AL. Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158765. [PMID: 32663609 DOI: 10.1016/j.bbalip.2020.158765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Li Y, Hou JJ, Wang X, Su S, Wang YM, Zhang J. New progress in research of intestinal microbiota in fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(23): 1355-1361 [DOI: 10.11569/wcjd.v29.i23.1355] [Reference Citation Analysis]
93 Di Bisceglie AM, Watts GF, Lavin P, Yu M, Bai R, Liu L. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids Health Dis 2020;19:239. [PMID: 33183320 DOI: 10.1186/s12944-020-01406-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Wu WK, Chen YH, Lee PC, Yang PJ, Chang CC, Liu KL, Hsu CC, Huang CC, Chuang HL, Sheen LY, Liu CJ, Wu MS. Mining Gut Microbiota From Bariatric Surgery for MAFLD. Front Endocrinol (Lausanne) 2021;12:612946. [PMID: 33897617 DOI: 10.3389/fendo.2021.612946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Baratta F, Ferro D, Pastori D, Colantoni A, Cocomello N, Coronati M, Angelico F, Del Ben M. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. Int J Environ Res Public Health 2021;18:8993. [PMID: 34501590 DOI: 10.3390/ijerph18178993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Cai J, Lin C, Lai S, Liu Y, Liang M, Qin Y, Liang X, Tan A, Gao Y, Lu Z, Wu C, Huang S, Yang X, Zhang H, Kuang J, Mo Z. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population. Lipids Health Dis 2021;20:145. [PMID: 34706716 DOI: 10.1186/s12944-021-01568-9] [Reference Citation Analysis]
97 Cataldi M, Manco F, Tarantino G. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. Int J Mol Sci 2021;22:12947. [PMID: 34884762 DOI: 10.3390/ijms222312947] [Reference Citation Analysis]
98 Lima RVC, Stefano JT, Malta FM, Pinho JRR, Carrilho FJ, Arrese M, Oliveira CP. Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. Biomedicines 2021;9:1751. [PMID: 34944567 DOI: 10.3390/biomedicines9121751] [Reference Citation Analysis]
99 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
101 Nguyen N, Rode A, Trillaud H, Aubé C, Manichon AF, Hocquelet A, Paisant A, Dao T, Nahon P, Ganne-Carrié N, Blaise L, Cauchy F, Sutter O, Séror O, Nault JC. Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. Liver Int 2021. [PMID: 34894060 DOI: 10.1111/liv.15129] [Reference Citation Analysis]
102 Ciardullo S, Monti T, Perseghin G. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2021;19:384-390.e1. [PMID: 32623006 DOI: 10.1016/j.cgh.2020.06.048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
103 Park H, Yoon EL, Kim M, Lee J, Kim JH, Cho S, Jun DW, Nah EH. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era. Hepatol Res 2021. [PMID: 34841632 DOI: 10.1111/hepr.13737] [Reference Citation Analysis]
104 Eslam M, Fan J, Mendez-sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. The Lancet Gastroenterology & Hepatology 2020;5:713-5. [DOI: 10.1016/s2468-1253(20)30090-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
105 Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00208-1. [PMID: 33618024 DOI: 10.1016/j.cgh.2021.02.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
106 Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille? J Clin Transl Hepatol 2021;9:931-8. [PMID: 34966656 DOI: 10.14218/JCTH.2021.00174] [Reference Citation Analysis]
107 Pan Z, Fan JG, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Curr Opin Pharmacol 2021;60:170-6. [PMID: 34455284 DOI: 10.1016/j.coph.2021.07.007] [Reference Citation Analysis]
108 Rispo A, Imperatore N, Guarino M, Tortora R, Alisi A, Cossiga V, Testa A, Ricciolino S, Fiorentino A, Morisco F. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. Liver Int 2021;41:788-98. [PMID: 33319459 DOI: 10.1111/liv.14767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Mikolasevic I, Domislovic V, Filipec Kanizaj T, Radic-Kristo D, Krznaric Z, Milovanovic T, Juric T, Klapan M, Skenderevic N, Delija B, Stevanovic T, Mijic A, Lukic A, Stimac D. Relationship between coffee consumption, sleep duration and smoking status with elastographic parameters of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. Int J Clin Pract 2021;75:e13770. [PMID: 33070425 DOI: 10.1111/ijcp.13770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease–Related Genetic Variants. Clinical Gastroenterology and Hepatology 2020. [DOI: 10.1016/j.cgh.2020.12.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
111 Senussi NH, McCarthy DM. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH). Ann Hepatol 2021;24:100526. [PMID: 34509272 DOI: 10.1016/j.aohep.2021.100526] [Reference Citation Analysis]
112 Yang X, Lu D, Wang R, Lian Z, Lin Z, Zhuo J, Chen H, Yang M, Tan W, Yang M, Wei X, Wei Q, Zheng S, Xu X. Single-cell profiling reveals distinct immune phenotypes that contribute to ischaemia-reperfusion injury after steatotic liver transplantation. Cell Prolif 2021;54:e13116. [PMID: 34469018 DOI: 10.1111/cpr.13116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
114 Fouad Y, Gomaa A, Attia D. The EMRG Consortium: a gate to identify the burden of metabolic (dysfunction)-associated fatty liver disease in Egypt. Ther Adv Endocrinol Metab 2021;12:20420188211054678. [PMID: 34733466 DOI: 10.1177/20420188211054678] [Reference Citation Analysis]
115 Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle 2021. [PMID: 34337887 DOI: 10.1002/jcsm.12754] [Reference Citation Analysis]
116 Ji L, Cai X, Bai Y, Li T. Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. Int J Gen Med 2021;14:2909-22. [PMID: 34234521 DOI: 10.2147/IJGM.S319759] [Reference Citation Analysis]
117 Huang S, Mu F, Li F, Wang W, Chen H, Lei L, Ma Y, Ding Y, Wang J. A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. J Diabetes Res 2020;2020:7867245. [PMID: 32724826 DOI: 10.1155/2020/7867245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Cannella R, Dasyam N, Seo SH, Furlan A, Borhani AA. Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chronic liver disease: effect of level of training and experience. Abdom Radiol (NY) 2021;46:960-8. [PMID: 32902660 DOI: 10.1007/s00261-020-02719-9] [Reference Citation Analysis]
119 Al-Nimer MS. Is COVID-19-induced liver injury different from other RNA viruses?‎ World J Meta-Anal 2021; 9(2): 108-127 [DOI: 10.13105/wjma.v9.i2.108] [Reference Citation Analysis]
120 Kositamongkol C, Charernboon T, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Charatcharoenwitthaya P, Phisalprapa P. Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome. Medicine (Baltimore) 2021;100:e27640. [PMID: 34871234 DOI: 10.1097/MD.0000000000027640] [Reference Citation Analysis]
121 Hashimoto Y, Hamaguchi M, Okamura T, Nakanishi N, Obora A, Kojima T, Fukui M. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig 2021. [PMID: 34561962 DOI: 10.1111/jdi.13678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. Nutrients 2021;13:3042. [PMID: 34578919 DOI: 10.3390/nu13093042] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
124 Lin SZ, Chen YW, Fan JG. Non‐alcoholic fatty liver disease to metabolic dysfunction‐associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. J Dig Dis 2020;21:604-9. [DOI: 10.1111/1751-2980.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Bayoumi A, Elsayed A, Han S, Petta S, Adams LA, Aller R, Khan A, García-Monzón C, Arias-Loste MT, Miele L, Latchoumanin O, Alenizi S, Gallego-Durán R, Fischer J, Berg T, Craxì A, Metwally M, Qiao L, Liddle C, Yki-Järvinen H, Bugianesi E, Romero-Gomez M, George J, Eslam M. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Adv Sci (Weinh) 2021;8:2004168. [PMID: 34141520 DOI: 10.1002/advs.202004168] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. J Clin Med 2021;10:5755. [PMID: 34945051 DOI: 10.3390/jcm10245755] [Reference Citation Analysis]
128 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
129 Nguyen VH, Le MH, Henry L, Cheung R. Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:3145. [PMID: 32941668 DOI: 10.1111/liv.14664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
130 Eslam M, George J. MAFLD: A game changer redefining fatty liver disease for adults and children. J Hepatol 2021;74:992-4. [PMID: 33453327 DOI: 10.1016/j.jhep.2021.01.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 [DOI: 10.1101/2020.09.23.20200535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Zhang CH, Sheng JQ, Xie WH, Luo XQ, Xue YN, Xu GL, Chen C. Mechanism and Basis of Traditional Chinese Medicine Against Obesity: Prevention and Treatment Strategies. Front Pharmacol 2021;12:615895. [PMID: 33762940 DOI: 10.3389/fphar.2021.615895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Zhao S, Wang Y, Wu W, Yang S, Feng L, Tao F, Ge W, Shen M, Xu W. Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance. Andrologia 2021;53:e14060. [PMID: 33782980 DOI: 10.1111/and.14060] [Reference Citation Analysis]
134 González-Arceo M, Gómez-Zorita S, Aguirre L, Portillo MP. Effect of Microalgae and Macroalgae Extracts on Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:2017. [PMID: 34208211 DOI: 10.3390/nu13062017] [Reference Citation Analysis]
135 Díaz LA, Idalsoaga F, Cannistra M, Candia R, Cabrera D, Barrera F, Soza A, Graham R, Riquelme A, Arrese M, Leise MD, Arab JP. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. World J Gastroenterol 2020; 26(48): 7693-7706 [PMID: 33505145 DOI: 10.3748/wjg.v26.i48.7693] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
136 Lee YB, Lee J. REPLY. Hepatology 2021;74:1135. [PMID: 33811378 DOI: 10.1002/hep.31844] [Reference Citation Analysis]
137 Mukherji A, Dachraoui M, Baumert TF. Perturbation of the circadian clock and pathogenesis of NAFLD. Metabolism 2020;111S:154337. [PMID: 32795560 DOI: 10.1016/j.metabol.2020.154337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
138 Cokan KB, Urlep Ž, Lorbek G, Matz-Soja M, Skubic C, Perše M, Jeruc J, Juvan P, Režen T, Rozman D. Chronic Disruption of the Late Cholesterol Synthesis Leads to Female-Prevalent Liver Cancer. Cancers (Basel) 2020;12:E3302. [PMID: 33182326 DOI: 10.3390/cancers12113302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Schnegelberger RD, Lang AL, Arteel GE, Beier JI. Environmental toxicant-induced maladaptive mitochondrial changes: A potential unifying mechanism in fatty liver disease? Acta Pharmaceutica Sinica B 2021;11:3756-67. [DOI: 10.1016/j.apsb.2021.09.002] [Reference Citation Analysis]
140 Spearman CW, Abdo A, Ambali A, Awuku YA, Kassianides C, Lesi OA, Ndomondo-Sigonda M, Onyekwere CA, Rwegasha J, Shewaye AB, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1047-56. [PMID: 34508669 DOI: 10.1016/S2468-1253(21)00296-X] [Reference Citation Analysis]
141 Méndez-Sánchez N, Córdova-Gallardo J, Barranco-Fragoso B, Eslam M. Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis. Front Immunol 2021;12:641240. [PMID: 33833761 DOI: 10.3389/fimmu.2021.641240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Hegyi PJ, Váncsa S, Ocskay K, Dembrovszky F, Kiss S, Farkas N, Erőss B, Szakács Z, Hegyi P, Pár G. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis. Front Med (Lausanne) 2021;8:626425. [PMID: 33777974 DOI: 10.3389/fmed.2021.626425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
144 Idalsoaga F, Kulkarni AV, Mousa OY, Arrese M, Arab JP. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Front Med (Lausanne) 2020;7:448. [PMID: 32974366 DOI: 10.3389/fmed.2020.00448] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
145 Polyzos SA, Mousiolis A, Mintziori G, Goulis DG. Nonalcoholic fatty liver disease in males with low testosterone concentrations. Diabetes Metab Syndr 2020;14:1571-7. [PMID: 32947757 DOI: 10.1016/j.dsx.2020.07.049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Shiha G, Mousa N. Non-alcoholic steatohepatitis or metabolic-associated fatty liver: time to change. Hepatobiliary Surg Nutr 2021;10:123-5. [PMID: 33575301 DOI: 10.21037/hbsn-20-438] [Reference Citation Analysis]
147 Mondal A, Bose D, Saha P, Sarkar S, Seth R, Kimono D, Albadrani M, Nagarkatti M, Nagarkatti P, Chatterjee S. Lipocalin 2 induces neuroinflammation and blood-brain barrier dysfunction through liver-brain axis in murine model of nonalcoholic steatohepatitis. J Neuroinflammation 2020;17:201. [PMID: 32622362 DOI: 10.1186/s12974-020-01876-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
148 Patel CJ, Claypool K. Prevalence of Fatty Liver Disease is Driven by Prediabetes and Diabetes: US NHANES 2017-2018. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00506-1. [PMID: 33965575 DOI: 10.1016/j.cgh.2021.05.003] [Reference Citation Analysis]
149 Viveiros A, Schaefer B, Panzer M, Henninger B, Plaikner M, Kremser C, Franke A, Franzenburg S, Hoeppner MP, Stauder R, Janecke A, Tilg H, Zoller H. MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes. Hepatology 2021. [PMID: 34048062 DOI: 10.1002/hep.31982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Marí M, de Gregorio E, de Dios C, Roca-Agujetas V, Cucarull B, Tutusaus A, Morales A, Colell A. Mitochondrial Glutathione: Recent Insights and Role in Disease. Antioxidants (Basel) 2020;9:E909. [PMID: 32987701 DOI: 10.3390/antiox9100909] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
152 Imai J, Kitamoto S, Kamada N. The pathogenic oral-gut-liver axis: new understandings and clinical implications. Expert Rev Clin Immunol 2021;17:727-36. [PMID: 34057877 DOI: 10.1080/1744666X.2021.1935877] [Reference Citation Analysis]
153 Bayoumi A, Grønbæk H, George J, Eslam M. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends Genet 2020;36:429-41. [PMID: 32396836 DOI: 10.1016/j.tig.2020.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
154 Li H, Guo M, An Z, Meng J, Jiang J, Song J, Wu W. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China. Int J Environ Res Public Health 2020;17:E1818. [PMID: 32168920 DOI: 10.3390/ijerph17061818] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
155 Díaz LA, Idalsoaga F, Fuentes-López E, Márquez-Lomas A, Ramírez CA, Roblero JP, Araujo RC, Higuera-de-la-Tijera F, Toro LG, Pazmiño G, Montes P, Hernandez N, Mendizabal M, Corsi O, Ferreccio C, Lazo M, Brahmania M, Singal AK, Bataller R, Arrese M, Arab JP. Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study. Hepatology 2021. [PMID: 34134172 DOI: 10.1002/hep.32016] [Reference Citation Analysis]
156 Chen YL, Li H, Li S, Xu Z, Tian S, Wu J, Liang XY, Li X, Liu ZL, Xiao J, Wei JY, Ma CY, Wu KN, Ran L, Kong LQ. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol 2021;21:212. [PMID: 33971822 DOI: 10.1186/s12876-021-01782-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
157 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
158 [DOI: 10.1101/2020.08.20.20176214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
159 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Reference Citation Analysis]
160 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
161 Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] [Reference Citation Analysis]
162 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
163 Tanase DM, Gosav EM, Petrov D, Jucan AE, Lacatusu CM, Floria M, Tarniceriu CC, Costea CF, Ciocoiu M, Rezus C. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. Diagnostics (Basel) 2021;11:2053. [PMID: 34829402 DOI: 10.3390/diagnostics11112053] [Reference Citation Analysis]
164 Saydmohammed M, Jha A, Mahajan V, Gavlock D, Shun TY, DeBiasio R, Lefever D, Li X, Reese C, Kershaw EE, Yechoor V, Behari J, Soto-Gutierrez A, Vernetti L, Stern A, Gough A, Miedel MT, Lansing Taylor D. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors. Exp Biol Med (Maywood) 2021;:15353702211009228. [PMID: 33957803 DOI: 10.1177/15353702211009228] [Reference Citation Analysis]
165 Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines 2021;9:1370. [PMID: 34680486 DOI: 10.3390/biomedicines9101370] [Reference Citation Analysis]
166 Han AL. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis. BMC Endocr Disord 2021;21:91. [PMID: 33933056 DOI: 10.1186/s12902-021-00758-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, Kerling A, Eigendorf J, Kück M, Hanke AA, Ensslen R, Nachbar L, Lauenstein D, Böthig D, Hilfiker-Kleiner D, Stiesch M, Terkamp C, Wedemeyer H, Haverich A, Tegtbur U. Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol 2021;12:e00371. [PMID: 34140456 DOI: 10.14309/ctg.0000000000000371] [Reference Citation Analysis]
168 Loeffelholz CV, Roth J, Coldewey SM, Birkenfeld AL. The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. Biomedicines 2021;9:1853. [PMID: 34944668 DOI: 10.3390/biomedicines9121853] [Reference Citation Analysis]
169 Kurosaki S, Nakagawa H, Hayata Y, Kawamura S, Matsushita Y, Yamada T, Uchino K, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kinoshita H, Tanaka Y, Nakatsuka T, Hirata Y, Tateishi K, Koike K. Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis. JHEP Rep 2021;3:100315. [PMID: 34345813 DOI: 10.1016/j.jhepr.2021.100315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 Ren TY, Li XY, Fan JG. Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try. Clin Mol Hepatol 2021;27:83-6. [PMID: 33317240 DOI: 10.3350/cmh.2020.0298] [Reference Citation Analysis]
171 Wang YL, Zhou X, Li DL, Ye JM. Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. Acta Pharmacol Sin 2021. [PMID: 33731774 DOI: 10.1038/s41401-021-00629-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
172 Miele L, Napodano C, Cesario A, De Magistris A, Pocino K, Basile U, Rapaccini GL, Gasbarrini A, Grieco A. COVID-19, adaptative immune response and metabolic-associated liver disease. Liver Int 2021;41:2560-77. [PMID: 34555255 DOI: 10.1111/liv.15061] [Reference Citation Analysis]
173 Shiha G, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2021;6:57-64. [PMID: 33181119 DOI: 10.1016/S2468-1253(20)30213-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
174 Alam S, Fahim SM. Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. World J Hepatol 2021; 13(10): 1203-1207 [PMID: 34786161 DOI: 10.4254/wjh.v13.i10.1203] [Reference Citation Analysis]
175 Alem SA, Gaber Y, Abdalla M, Said E, Fouad Y. Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. Journal of Hepatology 2021;74:1261-2. [DOI: 10.1016/j.jhep.2021.01.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
176 Jepsen P, Younossi ZM. The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. J Hepatol 2021;75 Suppl 1:S3-S13. [PMID: 34039490 DOI: 10.1016/j.jhep.2020.11.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
177 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
178 Stec DE, Hinds TD Jr. Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E9493. [PMID: 33327438 DOI: 10.3390/ijms21249493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
179 Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab 2021;50:101238. [PMID: 33892169 DOI: 10.1016/j.molmet.2021.101238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
180 Ismaiel A, Popa SL, Dumitrascu DL. Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: "Un Affaire de Coeur". Can J Gastroenterol Hepatol 2020;2020:8825615. [PMID: 33313020 DOI: 10.1155/2020/8825615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Wang M, Zhang R, Wang M, Zhang L, Ding Y, Tang Z, Wang H, Zhang W, Chen Y, Wang J. Genetic Polymorphism of Vitamin D Family Genes CYP2R1, CYP24A1, and CYP27B1 Are Associated With a High Risk of Non-alcoholic Fatty Liver Disease: A Case-Control Study. Front Genet 2021;12:717533. [PMID: 34484304 DOI: 10.3389/fgene.2021.717533] [Reference Citation Analysis]
182 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Reference Citation Analysis]
183 Corica D, Bottari A, Aversa T, Morabito LA, Curatola S, Alibrandi A, Ascenti G, Wasniewska M. Prospective assessment of liver stiffness by shear wave elastography in childhood obesity: a pilot study. Endocrine 2021. [PMID: 34302259 DOI: 10.1007/s12020-021-02828-5] [Reference Citation Analysis]
184 Jongraksak T, Sobhonslidsuk A, Jatchavala J, Warodomwichit D, Kaewduang P, Sungkanuparph S. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. Int J STD AIDS 2021;32:266-75. [DOI: 10.1177/0956462420960997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Zhang S, Xu M, Zhang W, Liu C, Chen S. Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications. Int J Mol Sci 2021;22:6110. [PMID: 34204038 DOI: 10.3390/ijms22116110] [Reference Citation Analysis]
186 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life (Basel) 2021;11:143. [PMID: 33672864 DOI: 10.3390/life11020143] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
187 Liu B, Xiang L, Ji J, Liu W, Chen Y, Xia M, Liu Y, Liu W, Zhu P, Jin Y, Han Y, Lu J, Li X, Zheng M, Lu Y. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest 2021;131:e144801. [PMID: 34651580 DOI: 10.1172/JCI144801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
188 Eslam M, George J. MAFLD: Now is the time to capitalize on the momentum. J Hepatol 2021;74:1262-3. [PMID: 33587953 DOI: 10.1016/j.jhep.2021.02.002] [Reference Citation Analysis]
189 Verdú E, Homs J, Boadas-Vaello P. Physiological Changes and Pathological Pain Associated with Sedentary Lifestyle-Induced Body Systems Fat Accumulation and Their Modulation by Physical Exercise. Int J Environ Res Public Health 2021;18:13333. [PMID: 34948944 DOI: 10.3390/ijerph182413333] [Reference Citation Analysis]
190 Yu S, Li C, Ji G, Zhang L. The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease. Front Pharmacol 2021;12:783393. [PMID: 34867414 DOI: 10.3389/fphar.2021.783393] [Reference Citation Analysis]
191 Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines 2021;9:353. [PMID: 33808404 DOI: 10.3390/biomedicines9040353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Dong Z, Wei Y, Tao M, Zhang L. Activation of the purinergic receptor P2X7 improves hepatosteatosis by promoting lipophagy. FEBS Lett 2021;595:2768-80. [PMID: 34652813 DOI: 10.1002/1873-3468.14207] [Reference Citation Analysis]
193 Ibrahim SH. Sinusoidal endotheliopathy in nonalcoholic steatohepatitis: therapeutic implications. Am J Physiol Gastrointest Liver Physiol 2021;321:G67-74. [PMID: 34037463 DOI: 10.1152/ajpgi.00009.2021] [Reference Citation Analysis]
194 Méndez-Sánchez N, Díaz-Orozco L, Córdova-Gallardo J. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. J Hepatol 2021;75:221-2. [PMID: 33892008 DOI: 10.1016/j.jhep.2021.04.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
195 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Tang L, Ma H, Eslam M, Wong GL, Zhu P, Chen S, Leeming DJ, Karsdal M, Li G, Huang O, Leung HH, Zhou Y, Feng Q, Jiang P, Gao L, Byrne CD, Targher G, George J, Wong VW, Zheng M. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism 2022;128:154958. [DOI: 10.1016/j.metabol.2021.154958] [Reference Citation Analysis]
197 Gawlik-Kotelnicka O, Strzelecki D. Probiotics as a Treatment for "Metabolic Depression"? A Rationale for Future Studies. Pharmaceuticals (Basel) 2021;14:384. [PMID: 33924064 DOI: 10.3390/ph14040384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Zhang C, Yang M. Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion. Front Med (Lausanne) 2021;8:789859. [PMID: 34869507 DOI: 10.3389/fmed.2021.789859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
199 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
200 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
201 Negi CK, Khan S, Dirven H, Bajard L, Bláha L. Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:4282. [PMID: 33924165 DOI: 10.3390/ijms22084282] [Reference Citation Analysis]
202 Cheng L, Chen T, Guo M, Liu P, Qiao X, Wei Y, She J, Li B, Xi W, Zhou J, Yuan Z, Wu Y, Liu J. Glycoursodeoxycholic acid ameliorates diet-induced metabolic disorders with inhibiting endoplasmic reticulum stress. Clin Sci (Lond) 2021;135:1689-706. [PMID: 34236076 DOI: 10.1042/CS20210198] [Reference Citation Analysis]
203 Huang J, Xue W, Wang M, Wu Y, Singh M, Zhu Y, Kumar R, Lin S. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis. Diabetes Metab Syndr Obes 2021;14:3417-25. [PMID: 34349535 DOI: 10.2147/DMSO.S316096] [Reference Citation Analysis]
204 Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol 2021;75:454-61. [PMID: 34019941 DOI: 10.1016/j.jhep.2021.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
205 Ismaiel A, Dumitrascu DL. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review. Eur J Clin Invest 2020;50:e13331. [PMID: 32589269 DOI: 10.1111/eci.13331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
206 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Reference Citation Analysis]
207 Kim TH, Hong DG, Yang YM. Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism. Biomedicines 2021;9:1903. [PMID: 34944728 DOI: 10.3390/biomedicines9121903] [Reference Citation Analysis]
208 Longo L, de Souza VEG, Stein DJ, de Freitas JS, Uribe-Cruz C, Torres ILS, Álvares-da-Silva MR. Transcranial direct current stimulation (tDCS) has beneficial effects on liver lipid accumulation and hepatic inflammatory parameters in obese rats. Sci Rep 2021;11:11037. [PMID: 34040131 DOI: 10.1038/s41598-021-90563-2] [Reference Citation Analysis]
209 Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 mo of the pandemic. JHEP Rep. 2020;2:100169. [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
210 Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 2021;:1-11. [PMID: 34904923 DOI: 10.1080/14728222.2021.2018418] [Reference Citation Analysis]
211 Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL, Escorcia FE. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules 2020;26:E4. [PMID: 33374953 DOI: 10.3390/molecules26010004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
212 Łykowska-Szuber L, Wołodźko K, Rychter AM, Szymczak-Tomczak A, Krela-Kaźmierczak I, Dobrowolska A. Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)-A Narrative Review. J Clin Med 2021;10:5048. [PMID: 34768568 DOI: 10.3390/jcm10215048] [Reference Citation Analysis]
213 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, Sun Y. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med 2021;16:68. [PMID: 34344394 DOI: 10.1186/s13020-021-00469-4] [Reference Citation Analysis]
215 Różański G, Kujawski S, Newton JL, Zalewski P, Słomko J. Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)-A Review. Nutrients 2021;13:2654. [PMID: 34444811 DOI: 10.3390/nu13082654] [Reference Citation Analysis]
216 Thomaides-Brears HB, Lepe R, Banerjee R, Duncker C. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY). 2020;45:3507-3522. [PMID: 32761254 DOI: 10.1007/s00261-020-02684-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
217 He X, Hu Y, Liu W, Zhu G, Zhang R, You J, Shao Y, Li Y, Zhang Z, Cui J, He Y, Ge G, Yang H. Deciphering the Effective Constituents and Mechanisms of Portulaca oleracea L. for Treating NASH via Integrating Bioinformatics Analysis and Experimental Pharmacology. Front Pharmacol 2022;12:818227. [DOI: 10.3389/fphar.2021.818227] [Reference Citation Analysis]
218 Ramos VM, Kowaltowski AJ, Kakimoto PA. Autophagy in Hepatic Steatosis: A Structured Review. Front Cell Dev Biol 2021;9:657389. [PMID: 33937257 DOI: 10.3389/fcell.2021.657389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Yang RX, Zou ZS, Zhong BH, Deng H, He FP, Shi JP, Zhao CY, Mi YQ, Zhou YJ, Di FS, Zheng RD, Du Q, Shang J, Popovic B, Chen J, Fan JG. The pathologic relevance of metabolic criteria in patients with biopsy-proven non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00112-0. [PMID: 34246549 DOI: 10.1016/j.hbpd.2021.06.002] [Reference Citation Analysis]
220 Gao F, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, George J, Zheng MH. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021;36:204-207. [PMID: 32436622 DOI: 10.1111/jgh.15112] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
221 Niriella MA, Ediriweera DS, Kasturiratne A, De Silva ST, Dassanayaka AS, De Silva AP, Kato N, Pathmeswaran A, Wickramasinghe AR, de Silva HJ. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. PLoS One 2021;16:e0245762. [PMID: 33534815 DOI: 10.1371/journal.pone.0245762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
222 Shepard CR. TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism. Front Endocrinol (Lausanne) 2020;11:613639. [PMID: 33584545 DOI: 10.3389/fendo.2020.613639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
223 Hegazy MA, Abd ALgwad I, Abuel Fadl S, Sayed Hassan M, Ahmed Rashed L, Hussein MA. Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity. Diabetes Metab Syndr Obes 2021;14:2247-54. [PMID: 34040409 DOI: 10.2147/DMSO.S291595] [Reference Citation Analysis]
224 Zheng J, Chen S, Cai Y, Lin S, Ke S, Liu L. Insufficient nocturnal sleep was associated with a higher risk of fibrosis in patients with diabetes with metabolic associated fatty liver disease. Ther Adv Endocrinol Metab 2020;11:2042018820947550. [PMID: 32973993 DOI: 10.1177/2042018820947550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism 2021;123:154868. [PMID: 34400217 DOI: 10.1016/j.metabol.2021.154868] [Reference Citation Analysis]
226 Fiorucci S, Biagioli M, Baldoni M, Ricci P, Sepe V, Zampella A, Distrutti E. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. Expert Opin Drug Discov 2021;:1-16. [PMID: 33849361 DOI: 10.1080/17460441.2021.1916465] [Reference Citation Analysis]
227 Oh JH, Lee JH, Cho MS, Kim H, Chun J, Lee JH, Yoon Y, Kang W. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. Nutrients 2021;13:1013. [PMID: 33801023 DOI: 10.3390/nu13031013] [Reference Citation Analysis]
228 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
229 Benedé-Ubieto R, Estévez-Vázquez O, Guo F, Chen C, Singh Y, Nakaya HI, Gómez Del Moral M, Lamas-Paz A, Morán L, López-Alcántara N, Reissing J, Bruns T, Avila MA, Santamaría E, Mazariegos MS, Woitok MM, Haas U, Zheng K, Juárez I, Martín-Villa JM, Asensio I, Vaquero J, Peligros MI, Argemi J, Bataller R, Ampuero J, Romero Gómez M, Trautwein C, Liedtke C, Bañares R, Cubero FJ, Nevzorova YA. An Experimental DUAL Model of Advanced Liver Damage. Hepatol Commun 2021;5:1051-68. [PMID: 34141989 DOI: 10.1002/hep4.1698] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
230 Chen C, Xin X, Liu Q, Tian HJ, Peng JH, Zhao Y, Hu YY, Feng Q. Geniposide and Chlorogenic Acid Combination Improves Non-Alcoholic Fatty Liver Disease Involving the Potent Suppression of Elevated Hepatic SCD-1. Front Pharmacol 2021;12:653641. [PMID: 34017254 DOI: 10.3389/fphar.2021.653641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Gliozzi M, Musolino V, Bosco F, Scicchitano M, Scarano F, Nucera S, Zito MC, Ruga S, Carresi C, Macrì R, Guarnieri L, Maiuolo J, Tavernese A, Coppoletta AR, Nicita C, Mollace R, Palma E, Muscoli C, Belzung C, Mollace V. Cholesterol homeostasis: Researching a dialogue between the brain and peripheral tissues. Pharmacol Res 2021;163:105215. [PMID: 33007421 DOI: 10.1016/j.phrs.2020.105215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
232 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
233 Zhu JZ, Yi HW, Huang W, Pang T, Zhou HP, Wu XD. Fatty liver diseases, mechanisms, and potential therapeutic plant medicines. Chin J Nat Med 2020;18:161-8. [PMID: 32245585 DOI: 10.1016/S1875-5364(20)30017-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Des Devel Ther 2021;15:3997-4009. [PMID: 34588764 DOI: 10.2147/DDDT.S315724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
235 Panera N, Meroni M, Longo M, Crudele A, Valenti L, Bellacchio E, Miele L, D'Oria V, Paolini E, Maggioni M, Fracanzani AL, Alisi A, Dongiovanni P. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine 2021;65:103249. [PMID: 33640795 DOI: 10.1016/j.ebiom.2021.103249] [Reference Citation Analysis]
236 Escutia-Gutiérrez R, Rodríguez-Sanabria JS, Monraz-Méndez CA, García-Bañuelos J, Santos-García A, Sandoval-Rodríguez A, Armendáriz-Borunda J. Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH. Sci Rep 2021;11:11709. [PMID: 34083664 DOI: 10.1038/s41598-021-91187-2] [Reference Citation Analysis]
237 Vural H, Armutcu F, Akyol O, Weiskirchen R. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. Clin Chim Acta 2021;523:374-9. [PMID: 34678296 DOI: 10.1016/j.cca.2021.10.018] [Reference Citation Analysis]
238 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
239 Nakano H, Wu S, Sakao K, Hara T, He J, Garcia S, Shetty K, Hou DX. Bilberry Anthocyanins Ameliorate NAFLD by Improving Dyslipidemia and Gut Microbiome Dysbiosis. Nutrients 2020;12:E3252. [PMID: 33114130 DOI: 10.3390/nu12113252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
240 Nawrot M, Peschard S, Lestavel S, Staels B. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021;123:154844. [PMID: 34343577 DOI: 10.1016/j.metabol.2021.154844] [Reference Citation Analysis]
241 Bayoumi A, Jalil I, Metwally M, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Miele L, Petta S, Craxì A, Gallego-Durán R, Fischer J, Berg T, Qiao L, Liddle C, Bugianesi E, Romero-Gomez M, George J, Eslam M. Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PLoS One 2020;15:e0243590. [PMID: 33306709 DOI: 10.1371/journal.pone.0243590] [Reference Citation Analysis]
242 Glyn-Owen K, Böhning D, Parkes J, Roderick P, Buchanan R. The combined effect of alcohol and body mass index on risk of chronic liver disease: A systematic review and meta-analysis of cohort studies. Liver Int 2021;41:1216-26. [PMID: 33283434 DOI: 10.1111/liv.14754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
243 Lamadrid P, Alonso-Peña M, San Segundo D, Arias-Loste M, Crespo J, Lopez-Hoyos M. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. Front Immunol 2021;12:651728. [PMID: 33859644 DOI: 10.3389/fimmu.2021.651728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
244 Pinto Gálvez SM, García-Mora U, Salgado-Álvarez GA, Cano-Contreras AD, Durán-Rosas C, Priego-Parra B, Triana-Romero A, Amieva-Balmori M, Roesch-Dietlen F, Francisco MDR, Chi-Cervera LA, Bernal-Reyes R, Martínez-Vázquez S, Martinez-Rodriguez LA, Méndez-Guerrero O, Icaza-Chávez ME, Remes-Troche JM. Body composition and phase angle by bioimpedance in patients with MAFLD. Gastroenterol Hepatol 2021:S0210-5705(21)00304-6. [PMID: 34742814 DOI: 10.1016/j.gastrohep.2021.10.003] [Reference Citation Analysis]
245 Caballano-infantes E, García-garcía A, Lopez-gomez C, Cueto A, Robles-diaz M, Ortega-alonso A, Martín-reyes F, Alvarez-alvarez I, Arranz-salas I, Ruiz-cabello F, Lucena IM, García-fuentes E, Andrade RJ, García-cortes M. Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines 2022;10:55. [DOI: 10.3390/biomedicines10010055] [Reference Citation Analysis]
246 Yki-Järvinen H, Luukkonen PK, Hodson L, Moore JB. Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34257427 DOI: 10.1038/s41575-021-00472-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
247 Vogel A, Brunner JS, Hajto A, Sharif O, Schabbauer G. Lipid scavenging macrophages and inflammation. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159066. [PMID: 34626791 DOI: 10.1016/j.bbalip.2021.159066] [Reference Citation Analysis]
248 Xie Y, Chen L, Xu Z, Li C, Ni Y, Hou M, Chen L, Chang H, Yang Y, Wang H, He R, Chen R, Qian L, Luo Y, Zhang Y, Li N, Zhu Y, Ji M, Liu Y. Predictive Modeling of MAFLD Based on Hsp90α and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model. Front Endocrinol (Lausanne) 2021;12:743202. [PMID: 34659125 DOI: 10.3389/fendo.2021.743202] [Reference Citation Analysis]
249 Rivera K, Quiñones V, Amigo L, Santander N, Salas-Pérez F, Xavier A, Fernández-Galilea M, Carrasco G, Cabrera D, Arrese M, Busso D, Andia ME, Rigotti A. Lipoprotein receptor SR-B1 deficiency enhances adipose tissue inflammation and reduces susceptibility to hepatic steatosis during diet-induced obesity in mice. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158909. [PMID: 33631309 DOI: 10.1016/j.bbalip.2021.158909] [Reference Citation Analysis]
250 Clayton M, Fabrellas N, Luo J, Alghamdi MG, Hafez A, Qadiri TA, Owise N, Attia D. From NAFLD to MAFLD: Nurse and allied health perspective. Liver Int 2021;41:683-91. [DOI: 10.1111/liv.14788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
251 Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol 2020; 12(9): 533-557 [PMID: 33033564 DOI: 10.4254/wjh.v12.i9.533] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
252 Duan JY, Lin X, Xu F, Shan SK, Guo B, Li FX, Wang Y, Zheng MH, Xu QS, Lei LM, Ou-Yang WL, Wu YY, Tang KX, Yuan LQ. Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization? Front Cell Dev Biol 2021;9:701788. [PMID: 34307381 DOI: 10.3389/fcell.2021.701788] [Reference Citation Analysis]
253 Huang J, Ou W, Wang M, Singh M, Liu Y, Liu S, Wu Y, Zhu Y, Kumar R, Lin S. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease. Risk Manag Healthc Policy 2021;14:491-501. [PMID: 33603515 DOI: 10.2147/RMHP.S285880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
254 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Alcedo KP, Rouse MA, Jung GS, Fu D, Minor M, Willcockson HH, Greene KG, Snider NT. CD73 Maintains Hepatocyte Metabolic Integrity and Mouse Liver Homeostasis in a Sex-Dependent Manner. Cell Mol Gastroenterol Hepatol 2021;12:141-57. [PMID: 33516905 DOI: 10.1016/j.jcmgh.2021.01.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:623-32. [PMID: 32552182 DOI: 10.1080/13543784.2020.1763302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
257 Sanz-garcía C, Fernández-iglesias A, Gracia-sancho J, Arráez-aybar LA, Nevzorova YA, Cubero FJ. The Space of Disse: The Liver Hub in Health and Disease. Livers 2021;1:3-26. [DOI: 10.3390/livers1010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
258 Jamwal R, Barlock BJ. Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. Pharmaceuticals (Basel) 2020;13:E222. [PMID: 32872474 DOI: 10.3390/ph13090222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
259 Chimienti G, Orlando A, Russo F, D'Attoma B, Aragno M, Aimaretti E, Lezza AMS, Pesce V. The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease. Genes (Basel) 2021;12:1439. [PMID: 34573421 DOI: 10.3390/genes12091439] [Reference Citation Analysis]
260 Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. [PMID: 33961787 DOI: 10.1016/S2468-1253(21)00020-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
261 Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. Journal of Hepatology 2021;74:1254-6. [DOI: 10.1016/j.jhep.2020.12.035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
262 Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients 2021;13:2830. [PMID: 34444990 DOI: 10.3390/nu13082830] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
263 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
264 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
265 Gatzios A, Rombaut M, Buyl K, De Kock J, Rodrigues RM, Rogiers V, Vanhaecke T, Boeckmans J. From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines 2022;10:161. [DOI: 10.3390/biomedicines10010161] [Reference Citation Analysis]
266 Lim HJ, Kim M. EZH2 as a Potential Target for NAFLD Therapy. Int J Mol Sci 2020;21:E8617. [PMID: 33207561 DOI: 10.3390/ijms21228617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Rahman MM, Kibria MG, Sultana N, Akhter M, Begum H, Haque MA, Haque R, Sarker SA, Ahmed F, Hasan M. Seroprevalence of Helicobacter pylori and its association with metabolic syndrome in a rural community of Bangladesh. JGH Open 2021;5:64-72. [PMID: 33490615 DOI: 10.1002/jgh3.12448] [Reference Citation Analysis]
268 Chen X, Chen S, Pang J, Tang Y, Ling W. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? J Hepatol 2021:S0168-8278(21)00421-9. [PMID: 34153396 DOI: 10.1016/j.jhep.2021.06.013] [Reference Citation Analysis]
269 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
270 Katsiki N, Ferrannini E, Mantzoros C. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism 2020;107:154218. [DOI: 10.1016/j.metabol.2020.154218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
271 Feng L, Zhao Y, Wang WL. Association between complement C3 and the prevalence of metabolic-associated fatty liver disease in a Chinese population: a cross-sectional study. BMJ Open 2021;11:e051218. [PMID: 34711595 DOI: 10.1136/bmjopen-2021-051218] [Reference Citation Analysis]
272 Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology. 2020;. [PMID: 32544255 DOI: 10.1002/hep.31420] [Cited by in Crossref: 47] [Cited by in F6Publishing: 57] [Article Influence: 47.0] [Reference Citation Analysis]
273 Li Y, Wang X, Zhang J, Zhang S, Jiao J. Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : A systematic review. Rev Endocr Metab Disord 2021. [PMID: 34396467 DOI: 10.1007/s11154-021-09681-x] [Reference Citation Analysis]
274 Massart J, Begriche K, Corlu A, Fromenty B. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease. IJMS 2022;23:1062. [DOI: 10.3390/ijms23031062] [Reference Citation Analysis]
275 O'Gorman P, Naimimohasses S, Monaghan A, Kennedy M, Melo AM, Ní Fhloinn D, Doherty DG, Beddy P, Finn SP, Moore JB, Gormley J, Norris S. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther 2020;52:1387-98. [PMID: 32717123 DOI: 10.1111/apt.15989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
276 Poniachik J, Roblero JP, Urzúa A, Cattaneo M. A new definition for non-alcoholic fatty liver disease. J Hepatol 2021;74:982-3. [PMID: 33340572 DOI: 10.1016/j.jhep.2020.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
277 Ando Y, Jou JH. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates.Clin Liver Dis (Hoboken). 2021;17:23-28. [PMID: 33552482 DOI: 10.1002/cld.1045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
278 Steinman JB, Salomao MA, Pajvani UB. Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. Liver Int 2021. [PMID: 34328687 DOI: 10.1111/liv.15025] [Reference Citation Analysis]
279 Zhang X, Mens MMJ, Abozaid YJ, Bos D, Darwish Murad S, de Knegt RJ, Ikram MA, Pan Q, Ghanbari M. Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Aliment Pharmacol Ther 2021;53:432-42. [PMID: 33244812 DOI: 10.1111/apt.16177] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
280 Li H, Huang W, Wang M, Chen P, Chen L, Zhang X. Tandem Mass Tag-based quantitative proteomics analysis of metabolic associated fatty liver disease induced by high fat diet in mice. Nutr Metab (Lond) 2020;17:97. [PMID: 33292312 DOI: 10.1186/s12986-020-00522-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Esmaili S, Langfelder P, Belgard TG, Vitale D, Azardaryany MK, Alipour Talesh G, Ramezani-Moghadam M, Ho V, Dvorkin D, Dervish S, Gloss BS, Grønbæk H, Liddle C, George J. Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. Cell Syst 2021;12:432-445.e7. [PMID: 33957084 DOI: 10.1016/j.cels.2021.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
282 Jianping W, Xuelian Z, Anjiang W, Haiying X. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:586-93. [PMID: 34039937 DOI: 10.1097/MCG.0000000000001556] [Reference Citation Analysis]
283 Kim HY, Baik SJ, Lee HA, Lee BK, Lee HS, Kim TH, Yoo K. Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease. Sci Rep 2020;10:17491. [PMID: 33060775 DOI: 10.1038/s41598-020-74659-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
284 Di Palo DM, Garruti G, Di Ciaula A, Molina-Molina E, Shanmugam H, De Angelis M, Portincasa P. Increased Colonic Permeability and Lifestyles as Contributing Factors to Obesity and Liver Steatosis. Nutrients 2020;12:E564. [PMID: 32098159 DOI: 10.3390/nu12020564] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
285 Ismaiel A, Spinu M, Budisan L, Leucuta DC, Popa SL, Chis BA, Berindan-Neagoe I, Olinic DM, Dumitrascu DL. Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease. J Clin Med 2021;10:5194. [PMID: 34768714 DOI: 10.3390/jcm10215194] [Reference Citation Analysis]
286 Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov 2021;16:125-34. [PMID: 33086894 DOI: 10.1080/17460441.2020.1811674] [Reference Citation Analysis]
287 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
288 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Evangelakos I, Schwinge D, Worthmann A, John C, Roeder N, Pertzborn P, Behrens J, Schramm C, Scheja L, Heeren J. Oxysterol 7-α Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality. Cells 2021;10:2656. [PMID: 34685636 DOI: 10.3390/cells10102656] [Reference Citation Analysis]
290 Bilic-Curcic I, Cigrovski Berkovic M, Virovic-Jukic L, Mrzljak A. Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals . World J Hepatol 2021; 13(1): 80-93 [PMID: 33584988 DOI: 10.4254/wjh.v13.i1.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Frohlich J, Mazza T, Sobolewski C, Foti M, Vinciguerra M. GDF11 rapidly increases lipid accumulation in liver cancer cells through ALK5-dependent signaling. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158920. [PMID: 33684566 DOI: 10.1016/j.bbalip.2021.158920] [Reference Citation Analysis]
292 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
293 Méndez-Sánchez N, Cerda-Reyes E, Higuera-de-la-Tijera F, Salas-García AK, Cabrera-Palma S, Cabrera-Álvarez G, Cortez-Hernández C, Pérez-Arredondo LA, Purón-González E, Coronado-Alejandro E, Panduro A, Rodríguez-Hernández H, Cruz-Ramón VC, Valencia-Rodríguez A, Qi X, Hamdan-Pérez N, Aguilar-Olivos NE, Barranco-Fragoso B, Ramírez-Pérez O, Vera-Barajas A. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. F1000Res 2020;9:56. [PMID: 32595949 DOI: 10.12688/f1000research.21918.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
294 Gaber Y, AbdAllah M, Salama A, Sayed M, Abdel Alem S, Nafady S. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34263707 DOI: 10.1080/17474124.2021.1952867] [Reference Citation Analysis]
295 Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021;13:1442. [PMID: 33923255 DOI: 10.3390/nu13051442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
296 Miele L, Perna A, Dajko M, Zocco MA, De Magistris A, Nicoletti TF, Biolato M, Marrone G, Liguori A, Maccora D, Valenza V, Rossi S, Riso V, Di Natale D, Gasbarrini A, Grieco A, Silvestri G. Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). Digestive and Liver Disease 2021. [DOI: 10.1016/j.dld.2020.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
297 Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. Front Med (Lausanne) 2021;8:781567. [PMID: 34957156 DOI: 10.3389/fmed.2021.781567] [Reference Citation Analysis]
298 Le Garf S, Nègre V, Anty R, Gual P. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. Biomedicines 2021;9:1915. [PMID: 34944730 DOI: 10.3390/biomedicines9121915] [Reference Citation Analysis]
299 Alsawat K, Hashim A, Alboraie M, Fouad Y. Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion. J Clin Transl Hepatol 2020;8:354-5. [PMID: 33083259 DOI: 10.14218/JCTH.2020.00049] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
300 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020; 12(12): 1168-1181 [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
301 Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int 2020;40:1016-7. [DOI: 10.1111/liv.14430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
302 Kouroumalis E, Voumvouraki A, Augoustaki A, Samonakis DN. Autophagy in liver diseases. World J Hepatol 2021; 13(1): 6-65 [PMID: 33584986 DOI: 10.4254/wjh.v13.i1.6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
303 Dai Y, He H, Li S, Yang L, Wang X, Liu Z, An Z. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:622589. [PMID: 33664710 DOI: 10.3389/fendo.2020.622589] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Ahmed M, Ahmed MH. Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic. World J Clin Cases 2021; 9(17): 4133-4142 [PMID: 34141776 DOI: 10.12998/wjcc.v9.i17.4133] [Reference Citation Analysis]
305 Liu J, Wang G, Wu Y, Guan Y, Luo Z, Zhao G, Jiang Y. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults. Nutrients 2021;13:4063. [PMID: 34836318 DOI: 10.3390/nu13114063] [Reference Citation Analysis]
306 Bae YS, Ko YS, Yun JM, Eo AY, Kim H. Association and Prediction of Subclinical Atherosclerosis by Nonalcoholic Fatty Liver Disease in Asymptomatic Patients. Can J Gastroenterol Hepatol 2020;2020:8820445. [PMID: 33354557 DOI: 10.1155/2020/8820445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Furuta K, Guo Q, Hirsova P, Ibrahim SH. Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis. Biology (Basel) 2020;9:E395. [PMID: 33198153 DOI: 10.3390/biology9110395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
308 Campos-Murguía A, Román-Calleja BM, Toledo-Coronado IV, González-Regueiro JA, Solís-Ortega AA, Kúsulas-Delint D, Cruz-Contreras M, Cruz-Yedra N, Cubero FJ, Nevzorova YA, Martínez-Cabrera CF, Moreno-Guillén P, Lozano-Cruz OA, Chapa-Ibargüengoitia M, Gulías-Herrero A, Aguilar-Salinas CA, Ruiz-Margáin A, Macías-Rodríguez RU. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis 2021;53:525-33. [PMID: 33551355 DOI: 10.1016/j.dld.2021.01.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
309 Liu D, Shen Y, Zhang R, Xun J, Wang J, Liu L, Steinhart C, Chen J, Lu H. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. J Gastroenterol Hepatol 2021;36:1670-8. [PMID: 33140878 DOI: 10.1111/jgh.15320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
310 Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Liver Int. 2020;40:1254-1261. [PMID: 32301554 DOI: 10.1111/liv.14478] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 35.5] [Reference Citation Analysis]
311 Blanco-Grau A, Gabriel-Medina P, Rodriguez-Algarra F, Villena Y, Lopez-Martínez R, Augustín S, Pons M, Cruz LM, Rando-Segura A, Enfedaque B, Riveiro M, Casis E, Ferrer-Costa R, Buti M, Rodriguez-Frias F. Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics (Basel) 2021;11:2236. [PMID: 34943471 DOI: 10.3390/diagnostics11122236] [Reference Citation Analysis]
312 Wen W, Wu P, Zhang Y, Chen Z, Sun J, Chen H. Comprehensive Analysis of NAFLD and the Therapeutic Target Identified. Front Cell Dev Biol 2021;9:704704. [PMID: 34616724 DOI: 10.3389/fcell.2021.704704] [Reference Citation Analysis]
313 Tada T, Nishimura T, Yoshida M, Iijima H. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. J Med Ultrasonics 2020;47:511-20. [DOI: 10.1007/s10396-020-01058-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
314 Eslam M, Ahmed A, Després JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 2021;6:743-53. [PMID: 34265276 DOI: 10.1016/S2468-1253(21)00132-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Polyzos SA, Kountouras J. Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. Annals of Hepatology 2020;19:579-80. [DOI: 10.1016/j.aohep.2020.07.001] [Reference Citation Analysis]
316 Goedeke L, Shulman GI. Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH. Mol Metab 2021;46:101178. [PMID: 33545391 DOI: 10.1016/j.molmet.2021.101178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
317 Ryou M, Stylopoulos N, Baffy G. Nonalcoholic fatty liver disease and portal hypertension. Explor Med 2020;1:149-69. [PMID: 32685936 DOI: 10.37349/emed.2020.00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
318 Yan H, Wu W, Chang X, Xia M, Ma S, Wang L, Gao J. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ 2021;12:1. [PMID: 33397443 DOI: 10.1186/s13293-020-00344-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Hajduch E, Lachkar F, Ferré P, Foufelle F. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:792. [PMID: 33669443 DOI: 10.3390/jcm10040792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Polyzos SA, Kang ES, Tsochatzis EA, Kechagias S, Ekstedt M, Xanthakos S, Lonardo A, Mantovani A, Tilg H, Côté I, Grefhorst A, Greene MW, Araujo-Vilar D, Alisi A, Casanueva F, Mantzoros CS. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism 2020;113:154413. [PMID: 33164861 DOI: 10.1016/j.metabol.2020.154413] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
321 Tang R, Li R, Li H, Ma XL, Du P, Yu XY, Ren L, Wang LL, Zheng WS. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. ACS Nano 2021. [PMID: 34705426 DOI: 10.1021/acsnano.1c02158] [Reference Citation Analysis]
322 Chen ZW, Tang K, Zhao YF, Chen YZ, Tang LJ, Li G, Huang OY, Wang XD, Targher G, Byrne CD, Zheng XW, Zheng MH. Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. Int J Med Sci 2021;18:3624-30. [PMID: 34790034 DOI: 10.7150/ijms.64458] [Reference Citation Analysis]
323 Shea S, Lionis C, Kite C, Atkinson L, Chaggar SS, Randeva HS, Kyrou I. Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress. Biomedicines 2021;9:1697. [PMID: 34829926 DOI: 10.3390/biomedicines9111697] [Reference Citation Analysis]
324 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Reference Citation Analysis]
325 Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med 2020;37:1793-806. [PMID: 32619031 DOI: 10.1111/dme.14356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
326 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
327 Eslam M, George J. MAFLD: A holistic view to redefining fatty liver disease. J Hepatol 2021;74:983-5. [PMID: 33453330 DOI: 10.1016/j.jhep.2020.12.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
328 Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism 2021;115:154433. [PMID: 33212070 DOI: 10.1016/j.metabol.2020.154433] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
329 Zhai M, Yan X, Liu J, Long Z, Zhao S, Li W, Liu Y, Hai C. Electromagnetic Fields Ameliorate Insulin Resistance and Hepatic Steatosis by Modulating Redox Homeostasis and SREBP-1c Expression in db/db Mice. Diabetes Metab Syndr Obes 2021;14:1035-42. [PMID: 33727836 DOI: 10.2147/DMSO.S294020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
331 Wang Y, Zhang W, Xia F, Wan H, Chen C, Chen Y, Wang N, Lu Y. Moderation effect of economic status in the association between early life famine exposure and MAFLD in adulthood. Liver Int 2021. [PMID: 34687278 DOI: 10.1111/liv.15088] [Reference Citation Analysis]
332 Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 2021. [PMID: 34953098 DOI: 10.1111/liv.15139] [Reference Citation Analysis]
333 Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, Lan Y, Hu S, Wang Y, Lu Y, Qu S, Wang L. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab 2021:dgab644. [PMID: 34467980 DOI: 10.1210/clinem/dgab644] [Reference Citation Analysis]
334 Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang Y, Zhou H, Li Y. Macrophage Polarization and Its Role in Liver Disease. Front Immunol 2021;12:803037. [PMID: 34970275 DOI: 10.3389/fimmu.2021.803037] [Reference Citation Analysis]
335 Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease. Nutrition 2021;83:111080. [PMID: 33348109 DOI: 10.1016/j.nut.2020.111080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
336 Osna NA, Ganesan M, Seth D, Wyatt TA, Kidambi S, Kharbanda KK. Second hits exacerbate alcohol-related organ damage: an update. Alcohol Alcohol 2021;56:8-16. [PMID: 32869059 DOI: 10.1093/alcalc/agaa085] [Reference Citation Analysis]
337 Di Costanzo A, Ronca A, D'Erasmo L, Manfredini M, Baratta F, Pastori D, Di Martino M, Ceci F, Angelico F, Del Ben M, Pavanello C, Turri M, Calabresi L, Favari E, Arca M. HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines 2020;8:E625. [PMID: 33352841 DOI: 10.3390/biomedicines8120625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
338 De Munck TJI, Boesch M, Verhaegh P, Masclee AAM, Jonkers D, van Pelt JF, du Plessis J, Korf H, Nevens F, Koek GH, Van der Merwe S, Verbeek J. Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease? PLoS One 2021;16:e0251822. [PMID: 33989346 DOI: 10.1371/journal.pone.0251822] [Reference Citation Analysis]
339 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 Simón J, Casado-Andrés M, Goikoetxea-Usandizaga N, Serrano-Maciá M, Martínez-Chantar ML. Nutraceutical Properties of Polyphenols against Liver Diseases. Nutrients 2020;12:E3517. [PMID: 33203174 DOI: 10.3390/nu12113517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
341 Conci S, Cipriani F, Donadon M, Marchitelli I, Ardito F, Famularo S, Perri P, Iaria M, Ansaloni L, Zanello M, La Barba G, Patauner S, Pinotti E, Molfino S, Germani P, Romano M, Sciannamea I, Ferrari C, Manzoni A, Troci A, Fumagalli L, Delvecchio A, Floridi A, Memeo R, Chiarelli M, Crespi M, Zimmitti G, Griseri G, Antonucci A, Zanus G, Tarchi P, Baiocchi GL, Zago M, Frena A, Ercolani G, Jovine E, Maestri M, Valle RD, Grazi GL, Romano F, Giuliante F, Torzilli G, Aldrighetti L, Ruzzenente A; He.RC.O.Le.S Group. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol 2021:S0748-7983(21)00636-3. [PMID: 34325939 DOI: 10.1016/j.ejso.2021.07.015] [Reference Citation Analysis]
342 Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS, Leung JK, Chim AM, Kong AP, Lui GC, Chan HL, Chu WC. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clin Gastroenterol Hepatol 2021;19:2161-2171.e5. [PMID: 33137486 DOI: 10.1016/j.cgh.2020.10.046] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
343 Thomas CE, Luu HN, Wang R, Xie G, Adams-Haduch J, Jin A, Koh WP, Jia W, Behari J, Yuan JM. Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancers (Basel) 2021;13:2648. [PMID: 34071196 DOI: 10.3390/cancers13112648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40:2082-2089. [PMID: 32478487 DOI: 10.1111/liv.14548] [Cited by in Crossref: 83] [Cited by in F6Publishing: 99] [Article Influence: 41.5] [Reference Citation Analysis]
345 Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne) 2021;8:595371. [PMID: 33718398 DOI: 10.3389/fmed.2021.595371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
346 Shek D, Chen D, Read SA, Ahlenstiel G. Examining the gut-liver axis in liver cancer using organoid models. Cancer Lett 2021;510:48-58. [PMID: 33891996 DOI: 10.1016/j.canlet.2021.04.008] [Reference Citation Analysis]
347 Hu X, Sun L, Guo Z, Wu C, Yu X, Li J. Management of COVID-19 Patients with Chronic Liver Diseases and Liver Transplants. Ann Hepatol 2021;:100653. [PMID: 34929350 DOI: 10.1016/j.aohep.2021.100653] [Reference Citation Analysis]
348 Cai Q, Gan C, Tang C, Wu H, Gao J. Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front Pharmacol 2021;12:784591. [PMID: 34887768 DOI: 10.3389/fphar.2021.784591] [Reference Citation Analysis]
349 Sahoo S, Singh D, Chakraborty P, Jolly MK. Emergent Properties of the HNF4α-PPARγ Network May Drive Consequent Phenotypic Plasticity in NAFLD. J Clin Med 2020;9:E870. [PMID: 32235813 DOI: 10.3390/jcm9030870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
350 Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020;50:e13338. [PMID: 32589264 DOI: 10.1111/eci.13338] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 12.5] [Reference Citation Analysis]
351 Hendrikx T, Binder CJ. Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:607011. [PMID: 33362721 DOI: 10.3389/fendo.2020.607011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
352 Spearman CW, Desalegn H, Ocama P, Awuku YA, Ojo O, Elsahhar M, Abdo AA, Ndububa DA, Fouad Y, Borodo MM, Ng'wanasayi M, Ally R, Elwakil R. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. J Hepatol 2021;74:1256-8. [PMID: 33484771 DOI: 10.1016/j.jhep.2021.01.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
353 Garcia-Martinez I, Alen R, Rada P, Valverde AM. Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis. Front Med (Lausanne) 2020;7:395. [PMID: 32850903 DOI: 10.3389/fmed.2020.00395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
354 Luedde T, Baumann U, Keitel V. Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD". J Hepatol 2021;75:1502-3. [PMID: 34520784 DOI: 10.1016/j.jhep.2021.08.032] [Reference Citation Analysis]
355 Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr 2020;14:1875-87. [PMID: 32998095 DOI: 10.1016/j.dsx.2020.09.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
356 Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
357 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
358 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
359 Luo Z, Xu W, Zhang Y, Di L, Shan J. A review of saponin intervention in metabolic syndrome suggests further study on intestinal microbiota. Pharmacol Res 2020;160:105088. [PMID: 32683035 DOI: 10.1016/j.phrs.2020.105088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
360 Mashek DG. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. Mol Metab 2021;50:101115. [PMID: 33186758 DOI: 10.1016/j.molmet.2020.101115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
361 Rebelos E, Iozzo P, Guzzardi MA, Brunetto MR, Bonino F. Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease. World J Gastroenterol 2021; 27(30): 4999-5018 [PMID: 34497431 DOI: 10.3748/wjg.v27.i30.4999] [Reference Citation Analysis]
362 Mendez-sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-ferrer J, Restrepo JC, Padilla-machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The Lancet Gastroenterology & Hepatology 2021;6:65-72. [DOI: 10.1016/s2468-1253(20)30340-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 32.0] [Reference Citation Analysis]
363 Arab JP, Díaz LA, Dirchwolf M, Mark H, Lazarus JV, Vaughan E, Méndez-Sánchez N, de Oliveira CP, Gadano A, Arrese M. NAFLD: Challenges and opportunities to address the public health challenge in Latin America. Ann Hepatol 2021;24:100359. [PMID: 34004366 DOI: 10.1016/j.aohep.2021.100359] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Tarantino G, Citro V, Balsano C. Liver-spleen axis in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:759-69. [PMID: 33878988 DOI: 10.1080/17474124.2021.1914587] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
365 Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
366 Pazoki R, Vujkovic M, Elliott J, Evangelou E, Gill D, Ghanbari M, van der Most PJ, Pinto RC, Wielscher M, Farlik M, Zuber V, de Knegt RJ, Snieder H, Uitterlinden AG, Lynch JA, Jiang X, Said S, Kaplan DE, Lee KM, Serper M, Carr RM, Tsao PS, Atkinson SR, Dehghan A, Tzoulaki I, Ikram MA, Herzig KH, Järvelin MR, Alizadeh BZ, O'Donnell CJ, Saleheen D, Voight BF, Chang KM, Thursz MR, Elliott P; Lifelines Cohort Study., VA Million Veteran Program. Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. Nat Commun 2021;12:2579. [PMID: 33972514 DOI: 10.1038/s41467-021-22338-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Kmeid M, Lukose G, Hodge K, Cho D, Kim KA, Lee H. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study. Histopathology 2021. [PMID: 34036629 DOI: 10.1111/his.14420] [Reference Citation Analysis]
368 Longo L, Rampelotto PH, Filippi-Chiela E, de Souza VEG, Salvati F, Cerski CT, da Silveira TR, Oliveira CP, Uribe-Cruz C, Álvares-da-Silva MR. Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis. World J Hepatol 2021; 13(12): 2052-2070 [DOI: 10.4254/wjh.v13.i12.2052] [Reference Citation Analysis]
369 Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021;14:215. [PMID: 33806527 DOI: 10.3390/ph14030215] [Reference Citation Analysis]
370 Deng Y, Zhao Q, Gong R. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018. Diabetes Metab Syndr Obes 2021;14:1751-61. [PMID: 33911888 DOI: 10.2147/DMSO.S292926] [Reference Citation Analysis]
371 Duseja A, Taneja S. Changing Nomenclature from Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Fatty Liver Disease - Not Only Premature But Also Confusing. J Clin Exp Hepatol 2021;11:278-9. [PMID: 33746456 DOI: 10.1016/j.jceh.2020.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
372 Eslam M, George J. Reply to: Correspondence on “A new definition for metabolic associated fatty liver disease: an international expert consensus statement”. Journal of Hepatology 2020;73:1268-9. [DOI: 10.1016/j.jhep.2020.06.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
373 Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00706-0. [PMID: 34224877 DOI: 10.1016/j.cgh.2021.06.042] [Reference Citation Analysis]
374 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
375 Israelsen M, Juel HB, Detlefsen S, Madsen BS, Rasmussen DN, Larsen TR, Kjærgaard M, Fernandes Jensen MJ, Stender S, Hansen T, Krag A, Thiele M; GALAXY and MicrobLiver consortiak. Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31628-1. [PMID: 33279778 DOI: 10.1016/j.cgh.2020.11.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
376 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Grzych G, Chávez-Talavera O, Descat A, Thuillier D, Verrijken A, Kouach M, Legry V, Verkindt H, Raverdy V, Legendre B, Caiazzo R, Van Gaal L, Goossens JF, Paumelle R, Francque S, Pattou F, Haas JT, Tailleux A, Staels B. NASH-related increases in plasma bile acid levels depend on insulin resistance. JHEP Rep 2021;3:100222. [PMID: 33615207 DOI: 10.1016/j.jhepr.2020.100222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
378 Guaraldi G, Milic J, Sebastiani G, Raggi P. Sarcopenic obesity at the crossroad of pathogenesis of cardiometabolic diseases. Atherosclerosis 2021;335:84-6. [PMID: 34563339 DOI: 10.1016/j.atherosclerosis.2021.09.006] [Reference Citation Analysis]
379 Jiang QQ, Liu BB, Xu KS. New insights into BMP9 signaling in liver diseases. Mol Cell Biochem 2021;476:3591-600. [PMID: 34019202 DOI: 10.1007/s11010-021-04182-6] [Reference Citation Analysis]
380 Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, Grønbæk H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front Med (Lausanne) 2020;7:615599. [PMID: 33490096 DOI: 10.3389/fmed.2020.615599] [Reference Citation Analysis]
381 Rodríguez-Antonio I, López-Sánchez GN, Reyes-Gómez VA, Contreras-Flores EH, Farías-García F, Espejel-Deloiza M, Durán-Padilla MA, Chablé-Montero F, Uribe M, Chávez-Tapia NC, Montalvo-Javé EE, Nuño-Lámbarri N. Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis. Ann Hepatol 2021;27:100651. [PMID: 34896638 DOI: 10.1016/j.aohep.2021.100651] [Reference Citation Analysis]
382 Mak LY, Fung J. The clinical and economic burden of non-alcoholic steatohepatitis in the Middle East: behind the scene. Hepatol Int 2021;15:860-2. [PMID: 34143330 DOI: 10.1007/s12072-021-10215-5] [Reference Citation Analysis]
383 Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016. Chin Med J (Engl) 2021;134:1593-601. [PMID: 34091530 DOI: 10.1097/CM9.0000000000001513] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
384 Ke Y, Liu S, Zhang Z, Hu J. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis 2021;20:55. [PMID: 34034750 DOI: 10.1186/s12944-021-01481-1] [Reference Citation Analysis]
385 Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Eur J Clin Invest 2021;51:e13519. [PMID: 33583033 DOI: 10.1111/eci.13519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
386 Dyah AA, Rahadina R. Metabolic associated fatty liver disease and adverse maternal and fetal outcomes: a systematic review and meta-analysis. Clin Exp Hepatol 2021;7:305-11. [PMID: 34712833 DOI: 10.5114/ceh.2021.109228] [Reference Citation Analysis]
387 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Reference Citation Analysis]
388 Grefhorst A, van de Peppel IP, Larsen LE, Jonker JW, Holleboom AG. The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:601627. [PMID: 33597924 DOI: 10.3389/fendo.2020.601627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
389 Cao JY, Artunduaga M, Schooler GR. Hepatic manifestations of systemic disease: an imaging-based review. Pediatr Radiol 2021. [PMID: 34797394 DOI: 10.1007/s00247-021-05222-5] [Reference Citation Analysis]
390 Ruuskanen MO, Åberg F, Männistö V, Havulinna AS, Méric G, Liu Y, Loomba R, Vázquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa V, Jain M, Knight R, Lahti L, Niiranen TJ. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes 2021;13:1-22. [PMID: 33651661 DOI: 10.1080/19490976.2021.1888673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
391 Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, Rivera-Iñiguez I, Campos-Medina L, Roman S. Adherence to a Fish-Rich Dietary Pattern Is Associated with Chronic Hepatitis C Patients Showing Low Viral Load: Implications for Nutritional Management. Nutrients 2021;13:3337. [PMID: 34684338 DOI: 10.3390/nu13103337] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Coman LI, Coman OA, Bădărău IA, Păunescu H, Ciocîrlan M. Association between Liver Cirrhosis and Diabetes Mellitus: A Review on Hepatic Outcomes. J Clin Med 2021;10:E262. [PMID: 33445629 DOI: 10.3390/jcm10020262] [Reference Citation Analysis]
393 Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, Hwang J, Qi X, Cua IH, Suh JI, Park JG, Putcharoen O, Kaewdech A, Piratvisuth T, Treeprasertsuk S, Park S, Wejnaruemarn S, Payawal DA, Baatarkhuu O, Ahn SH, Yeo CD, Alonzo UR, Chinbayar T, Loho IM, Yokosuka O, Jafri W, Tan S, Soo LI, Tanwandee T, Gani R, Anand L, Esmail ES, Khalaf M, Alam S, Lin CY, Chuang WL, Soin AS, Garg HK, Kalista K, Batsukh B, Purnomo HD, Dara VP, Rathi P, Al Mahtab M, Shukla A, Sharma MK, Omata M;  APASL COVID Task Force; APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14:690-700. [PMID: 32623632 DOI: 10.1007/s12072-020-10072-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 29.5] [Reference Citation Analysis]
394 Wang MF, Wan B, Wu YL, Huang JF, Zhu YY, Li YB. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection. World J Gastroenterol 2021; 27(4): 336-344 [PMID: 33584066 DOI: 10.3748/wjg.v27.i4.336] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
395 Zhao J, Zhao Y, Hu Y, Peng J. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. Cell Mol Biol Lett 2021;26:32. [PMID: 34233623 DOI: 10.1186/s11658-021-00276-7] [Reference Citation Analysis]
396 Bayoumi A, Shatat M, Eslam M. Metabolic associated fatty liver disease and cancer risk: causal role or epiphenomenon? Hepatobiliary Surg Nutr 2020;9:774-6. [PMID: 33299832 DOI: 10.21037/hbsn.2020.03.05] [Reference Citation Analysis]
397 Remmerie A, Martens L, Thoné T, Castoldi A, Seurinck R, Pavie B, Roels J, Vanneste B, De Prijck S, Vanhockerhout M, Binte Abdul Latib M, Devisscher L, Hoorens A, Bonnardel J, Vandamme N, Kremer A, Borghgraef P, Van Vlierberghe H, Lippens S, Pearce E, Saeys Y, Scott CL. Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. Immunity 2020;53:641-657.e14. [PMID: 32888418 DOI: 10.1016/j.immuni.2020.08.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
398 Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, Bourke L, Simmons D, Roberts SK. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. J Gastroenterol Hepatol 2021. [PMID: 34693553 DOI: 10.1111/jgh.15723] [Reference Citation Analysis]
399 Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
400 Kotlyarov S, Bulgakov A. Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease. Cells 2021;10:2978. [PMID: 34831201 DOI: 10.3390/cells10112978] [Reference Citation Analysis]
401 Lin YC, Wu CC, Ni YH. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Front Pediatr 2020;8:603654. [PMID: 33363067 DOI: 10.3389/fped.2020.603654] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
402 Meroni M, Longo M, Tria G, Dongiovanni P. Genetics Is of the Essence to Face NAFLD. Biomedicines 2021;9:1359. [PMID: 34680476 DOI: 10.3390/biomedicines9101359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
404 Kim HG, Wang JH, Kim HS, Lee JS, Im HJ, Lee SB, Lee DS, Hur GM, Son CG. Animal Evidence for Synergistic Induction of Hepatic Injury by Dietary Fat and Alcohol Consumption and Its Potential Mechanisms. J Pers Med 2021;11:287. [PMID: 33918059 DOI: 10.3390/jpm11040287] [Reference Citation Analysis]
405 Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nguyen MH. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. Hepatol Commun 2021;5:122-32. [PMID: 33437906 DOI: 10.1002/hep4.1606] [Reference Citation Analysis]
406 Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Reference Citation Analysis]
407 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Reference Citation Analysis]
408 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2021. [PMID: 34741169 DOI: 10.1038/s41577-021-00639-3] [Reference Citation Analysis]
409 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
410 Zheng KI, Eslam M, George J, Zheng MH. When a new definition overhauls perceptions of MAFLD related cirrhosis care. Hepatobiliary Surg Nutr 2020;9:801-4. [PMID: 33299840 DOI: 10.21037/hbsn-20-725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
411 Meroni M, Longo M, Paolini E, Alisi A, Miele L, De Caro ER, Pisano G, Maggioni M, Soardo G, Valenti LV, Fracanzani AL, Dongiovanni P. The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers (Basel) 2021;13:1783. [PMID: 33917919 DOI: 10.3390/cancers13081783] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
412 Danielsson O, Nissinen MJ, Jula A, Salomaa V, Männistö S, Lundqvist A, Perola M, Åberg F. Waist and hip circumference are independently associated with the risk of liver disease in population-based studies. Liver Int 2021. [PMID: 34510711 DOI: 10.1111/liv.15053] [Reference Citation Analysis]
413 Wang X, Sun K, Zhou Y, Wang H, Zhou Y, Liu S, Nie Y, Li Y. NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. Biochem Biophys Res Commun 2021;534:734-9. [PMID: 33213837 DOI: 10.1016/j.bbrc.2020.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
414 Guerreiro GTS, Longo L, Fonseca MA, de Souza VEG, Álvares-da-Silva MR. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int 2021;15:380-91. [PMID: 33694066 DOI: 10.1007/s12072-021-10157-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
415 Hydes T, Buchanan R, Kennedy OJ, Fraser S, Parkes J, Roderick P. Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open 2020;10:e040970. [PMID: 32988952 DOI: 10.1136/bmjopen-2020-040970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
416 Ma Y, Li J, Ju Z, Huang W, Wang Z, Yang L, Ding L. Danning tablets alleviate high fat diet-induced obesity and fatty liver in mice via modulating SREBP pathway. J Ethnopharmacol 2021;279:114320. [PMID: 34116189 DOI: 10.1016/j.jep.2021.114320] [Reference Citation Analysis]
417 Mantovani A, Dalbeni A. NAFLD, MAFLD and DAFLD. Dig Liver Dis 2020;52:1519-20. [PMID: 33012657 DOI: 10.1016/j.dld.2020.09.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
418 Ismaiel A, Leucuta DC, Popa SL, Dumitrascu DL. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis. J Clin Med 2021;10:3029. [PMID: 34300193 DOI: 10.3390/jcm10143029] [Reference Citation Analysis]
419 Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:11128. [PMID: 34681787 DOI: 10.3390/ijms222011128] [Reference Citation Analysis]
420 Sierra F, Cárdenas A. Re: Fouad Y, et al. The NAFLD-MAFLD debate: Eminence versus evidence. Liver Int. 2020 Nov 21. doi: 10.1111/liv.14739. Liver Int 2021;41:1162-3. [PMID: 33280222 DOI: 10.1111/liv.14750] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
421 Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW; Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol 2021;27:257-69. [PMID: 33751877 DOI: 10.3350/cmh.2021.0067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
422 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
423 Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z. The times they are a-changin' (for NAFLD as well). J Hepatol 2020;73:1307-9. [PMID: 32890593 DOI: 10.1016/j.jhep.2020.08.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
424 Pan MX, Zheng CY, Deng YJ, Tang KR, Nie H, Xie JQ, Liu DD, Tu GF, Yang QH, Zhang YP. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease. J Integr Med 2021;19:428-38. [PMID: 34426178 DOI: 10.1016/j.joim.2021.07.004] [Reference Citation Analysis]
425 Li J, Yang H, Yeh M, Le MH, Le AK, Yeo YH, Dai C, Barnett S, Zhang JQ, Huang J, Trinh HN, Wong C, Wong C, Hoang JK, Cheung R, Yu M, Nguyen MH. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. The Journal of Infectious Diseases 2021;224:294-302. [DOI: 10.1093/infdis/jiaa739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
426 Molina-Molina E, Shanmugam H, Di Ciaula A, Grattagliano I, Di Palo DM, Palmieri VO, Portincasa P. (13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle. JHEP Rep 2021;3:100203. [PMID: 33490935 DOI: 10.1016/j.jhepr.2020.100203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
427 Moreno-vedia J, Girona J, Ibarretxe D, Masana L, Rodríguez-calvo R. Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease. Biomedicines 2022;10:197. [DOI: 10.3390/biomedicines10010197] [Reference Citation Analysis]
428 Meroni M, Longo M, Fracanzani AL, Dongiovanni P. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine 2020;57:102866. [PMID: 32629394 DOI: 10.1016/j.ebiom.2020.102866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
429 Parry SA, Turner MC, Hodson L. Lifestyle interventions affecting hepatic fatty acid metabolism. Curr Opin Clin Nutr Metab Care 2020;23:373-9. [PMID: 32833701 DOI: 10.1097/MCO.0000000000000687] [Reference Citation Analysis]
430 López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech 2021;14:dmm049173. [PMID: 34850865 DOI: 10.1242/dmm.049173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 de Freitas Júnior JR, Ribeiro IB, de Moura DTH, Sagae VMT, de Souza GMV, de Oliveira GHP, Sánchez-Luna SA, de Souza TF, de Moura ETH, de Oliveira CPMS, Bernardo WM, de Moura EGH. Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis. World J Hepatol 2021; 13(7): 815-829 [PMID: 34367502 DOI: 10.4254/wjh.v13.i7.815] [Reference Citation Analysis]
432 Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J, Zheng MH. From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chin Med J (Engl) 2020;133:2271-3. [PMID: 32701591 DOI: 10.1097/CM9.0000000000000981] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 21.0] [Reference Citation Analysis]
433 Hou XD, Yan N, Du YM, Liang H, Zhang ZF, Yuan XL. Consumption of Wild Rice (Zizania latifolia) Prevents Metabolic Associated Fatty Liver Disease through the Modulation of the Gut Microbiota in Mice Model. Int J Mol Sci 2020;21:E5375. [PMID: 32751062 DOI: 10.3390/ijms21155375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Han MAT, Olivo R, Choi CJ, Pyrsopoulos N. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World J Hepatol 2021; 13(12): 1991-2004 [DOI: 10.4254/wjh.v13.i12.1991] [Reference Citation Analysis]
435 Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 2021. [PMID: 34129272 DOI: 10.1111/hepr.13685] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
436 Li M, Zhao Z, Qin G, Chen L, Lu J, Huo Y, Chen L, Zeng T, Xu M, Chen Y, Wang T, Wang S, Xu Y, Shi L, Tang X, Su Q, Yu X, Yan L, Wan Q, Chen G, Gao Z, Wang G, Shen F, Luo Z, Zhang Y, Liu C, Wang Y, Hu R, Ye Z, Wu S, Deng H, Yang T, Li Q, Qin Y, Mu Y, Zhao J, Ning G, Bi Y, Xu Y, Wang W. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes. Metabolism 2021;124:154874. [PMID: 34517014 DOI: 10.1016/j.metabol.2021.154874] [Reference Citation Analysis]
437 Lombardi R, Iuculano F, Pallini G, Fargion S, Fracanzani AL. Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. Int J Mol Sci 2020;21:E8761. [PMID: 33228237 DOI: 10.3390/ijms21228761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
438 Kositamongkol C, Kanchanasurakit S, Auttamalang C, Inchai N, Kabkaew T, Kitpark S, Chaiyakunapruk N, Duangjai A, Saokaew S, Phisalprapa P. Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis. Front Pharmacol 2021;12:786596. [PMID: 34966282 DOI: 10.3389/fphar.2021.786596] [Reference Citation Analysis]
439 Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B. Curcumin in Metabolic Health and Disease. Nutrients 2021;13:4440. [PMID: 34959992 DOI: 10.3390/nu13124440] [Reference Citation Analysis]
440 Luo X, Luo SZ, Xu ZX, Zhou C, Li ZH, Zhou XY, Xu MY. Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease. World J Gastroenterol 2021; 27(14): 1419-1434 [PMID: 33911465 DOI: 10.3748/wjg.v27.i14.1419] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Tan SY, Georgousopoulou EN, Cardoso BR, Daly RM, George ES. Associations between nut intake, cognitive function and non-alcoholic fatty liver disease (NAFLD) in older adults in the United States: NHANES 2011-14. BMC Geriatr 2021;21:313. [PMID: 34001034 DOI: 10.1186/s12877-021-02239-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
442 Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. J Clin Transl Hepatol 2021;9:71-80. [PMID: 33604257 DOI: 10.14218/JCTH.2020.00082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
443 Dong HN, Park SY, Le CT, Choi DH, Cho EH. Irisin Regulates the Functions of Hepatic Stellate Cells. Endocrinol Metab (Seoul) 2020;35:647-55. [PMID: 32981307 DOI: 10.3803/EnM.2020.658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
444 Guo B, Guo Y, Nima Q, Feng Y, Wang Z, Lu R, Baimayangji, Ma Y, Zhou J, Xu H, Chen L, Chen G, Li S, Tong H, Ding X, Zhao X. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. J Hepatol 2021:S0168-8278(21)02153-X. [PMID: 34883157 DOI: 10.1016/j.jhep.2021.10.016] [Reference Citation Analysis]
445 Mazzini GS, Augustin T, Noria S, Romero-Marrero C, Li N, Hameed B, Eisenberg D, Azagury DE, Ikramuddin S. ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis. Surg Obes Relat Dis 2021:S1550-7289(21)00548-7. [PMID: 34953742 DOI: 10.1016/j.soard.2021.11.015] [Reference Citation Analysis]
446 Fu LY, Wang SW, Hu MY, Jiang ZL, Shen LL, Zhou YP, Guo JM, Hu YR. Circular RNAs in liver diseases: Mechanisms and therapeutic targets. Life Sci 2021;264:118707. [PMID: 33144187 DOI: 10.1016/j.lfs.2020.118707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
447 Park H, Yoon EL, Kim M, Kim JH, Cho S, Jun DW, Nah EH. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver. J Clin Med 2021;10:4625. [PMID: 34640643 DOI: 10.3390/jcm10194625] [Reference Citation Analysis]
448 Zakaria Z, Othman ZA, Bagi Suleiman J, Jalil NAC, Ghazali WSW, Mohamed M. Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation. Vet Sci 2021;8:274. [PMID: 34822647 DOI: 10.3390/vetsci8110274] [Reference Citation Analysis]
449 Kamalraj N, Sathishkumar M, Arunvignesh M, Baskar V, Jebarani S, Amutha A, Deepa M, Shanthi Rani CS, Chandru S, Unnikrishnan R, Anjana RM, Harish M, Mohan V. Retrospective analysis (2009-2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India. Diabetes Metab Syndr 2021;15:102261. [PMID: 34464909 DOI: 10.1016/j.dsx.2021.102261] [Reference Citation Analysis]
450 Starekova J, Hernando D, Pickhardt PJ, Reeder SB. Quantification of Liver Fat Content with CT and MRI: State of the Art. Radiology 2021;301:250-62. [PMID: 34546125 DOI: 10.1148/radiol.2021204288] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Ore A, Akinloye OA. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions. Medicina (Kaunas) 2021;57:822. [PMID: 34441028 DOI: 10.3390/medicina57080822] [Reference Citation Analysis]
452 Pugliese N, Plaz Torres MC, Petta S, Valenti L, Giannini EG, Aghemo A. Is there an 'ideal' diet for patients with NAFLD? Eur J Clin Invest 2021;:e13659. [PMID: 34309833 DOI: 10.1111/eci.13659] [Reference Citation Analysis]
453 Wu T, Ye J, Shao C, Li F, Lin Y, Ma Q, Wang W, Feng S, Zhong B. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:691556. [PMID: 34899591 DOI: 10.3389/fendo.2021.691556] [Reference Citation Analysis]
454 Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134:8-19. [PMID: 33323806 DOI: 10.1097/cm9.0000000000001263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
455 Chimoriya R, Piya MK, Simmons D, Ahlenstiel G, Ho V. The Use of Two-Dimensional Shear Wave Elastography in People with Obesity for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. J Clin Med 2020;10:E95. [PMID: 33383965 DOI: 10.3390/jcm10010095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
456 Zhao QY, Ge LH, Zhang K, Chen HF, Zhan XX, Yang Y, Dang QL, Zheng Y, Zhou HB, Lyu JX, Fang HZ. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models. Zool Res 2020;41:539-51. [PMID: 32786176 DOI: 10.24272/j.issn.2095-8137.2020.051] [Reference Citation Analysis]
457 Chaney A. Obesity and Nonalcoholic Fatty Liver Disease. Nurs Clin North Am 2021;56:543-52. [PMID: 34749893 DOI: 10.1016/j.cnur.2021.07.009] [Reference Citation Analysis]
458 Gallo P, De Vincentis A, Bandinelli S, Ferrucci L, Picardi A, Antonelli Incalzi R, Vespasiani-Gentilucci U. Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients. Aging Clin Exp Res 2021. [PMID: 34506007 DOI: 10.1007/s40520-021-01979-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
459 Hwang TI, Han AL. Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease. Int J Environ Res Public Health 2021;18:13145. [PMID: 34948754 DOI: 10.3390/ijerph182413145] [Reference Citation Analysis]
460 Thoen RU, Longo L, Neto SC, Álvares-da-Silva MR. Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease. Clin Res Hepatol Gastroenterol 2021;45:101638. [PMID: 33662773 DOI: 10.1016/j.clinre.2021.101638] [Reference Citation Analysis]
461 Vos DY, van de Sluis B. Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD). Mol Metab 2021;50:101146. [PMID: 33348067 DOI: 10.1016/j.molmet.2020.101146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
462 Calapod OP, Marin AM, Onisai M, Tribus LC, Pop CS, Fierbinteanu-Braticevici C. The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis. Medicina (Kaunas) 2021;57:434. [PMID: 33946377 DOI: 10.3390/medicina57050434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 Blagotinšek Cokan K, Urlep Ž, Moškon M, Mraz M, Kong XY, Eskild W, Rozman D, Juvan P, Režen T. Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans. Int J Mol Sci 2021;22:E832. [PMID: 33467660 DOI: 10.3390/ijms22020832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Chi ZC. Research status and progress of metabolic associated fatty liver disease. Shijie Huaren Xiaohua Zazhi 2022; 30(1): 1-16 [DOI: 10.11569/wcjd.v30.i1.1] [Reference Citation Analysis]
465 Dongiovanni P, Meroni M, Longo M, Fracanzani AL. MAFLD in COVID-19 patients: an insidious enemy. Expert Review of Gastroenterology & Hepatology 2020;14:867-72. [DOI: 10.1080/17474124.2020.1801417] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
466 Carretero Gómez J, Ena J, Seguí Ripoll JM, Carrasco-Sánchez FJ, Gómez Huelgas R, Casas Rojo JM, Suárez Tembra M, Carabantes Rueda JJ, Arévalo Lorido JC. Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity. Curr Med Res Opin 2021;:1-7. [PMID: 34357836 DOI: 10.1080/03007995.2021.1965563] [Reference Citation Analysis]
467 Kolaric TO, Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, Raguz-Lucic N, Wu GY, Smolic M. Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. J Clin Transl Hepatol 2021;9:731-7. [PMID: 34722188 DOI: 10.14218/JCTH.2020.00091] [Reference Citation Analysis]
468 Liang Y, Zou L, Tian Y, Zhou S, Chen X, Lin C. Dietary and metabolic risk of neuropsychiatric disorders: insights from animal models. Br J Nutr 2021;:1-17. [PMID: 33618780 DOI: 10.1017/S0007114521000659] [Reference Citation Analysis]
469 Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69:1545-1547. [PMID: 32414813 DOI: 10.1136/gutjnl-2020-321611] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 27.0] [Reference Citation Analysis]
470 Zaky S, Alboraie M, El Badry M, Metwally MA, Abdelaziz A, Fouad Y, Abd-Elsalam S, Mahmoud A, Shiha G, Baki AA, El Kassas M, Esmat G. Management of liver disease patients in different clinical situations during COVID-19 pandemic. Egypt Liver J 2021;11:21. [PMID: 34777868 DOI: 10.1186/s43066-021-00091-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
471 Kanda T, Sasaki R, Masuzaki R, Takahashi H, Mizutani T, Matsumoto N, Nirei K, Moriyama M. Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease. Int J Mol Sci 2020;21:E6384. [PMID: 32887515 DOI: 10.3390/ijms21176384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
472 Xu L, Liu W, Bai F, Xu Y, Liang X, Ma C, Gao L. Hepatic Macrophage as a Key Player in Fatty Liver Disease. Front Immunol 2021;12:708978. [PMID: 34956171 DOI: 10.3389/fimmu.2021.708978] [Reference Citation Analysis]
473 Uchida S, Kauppinen S. Long Non-Coding RNAs in Liver Cancer and Nonalcoholic Steatohepatitis. Noncoding RNA 2020;6:E34. [PMID: 32872482 DOI: 10.3390/ncrna6030034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
474 Wu YL, Kumar R, Wang MF, Singh M, Huang JF, Zhu YY, Lin S. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2021; 27(34): 5753-5763 [PMID: 34629799 DOI: 10.3748/wjg.v27.i34.5753] [Reference Citation Analysis]
475 Zheng MH. Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:793-4. [PMID: 34966641 DOI: 10.14218/JCTH.2021.00439] [Reference Citation Analysis]
476 Yu J, Zhu C, Wang X, Kim K, Bartolome A, Dongiovanni P, Yates KP, Valenti L, Carrer M, Sadowski T, Qiang L, Tabas I, Lavine JE, Pajvani UB. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Sci Transl Med 2021;13:eabe1692. [PMID: 34162749 DOI: 10.1126/scitranslmed.abe1692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Park H, Yoon EL, Cho S, Nah EH, Jun DW. Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era? J Hepatol 2021;75:725-6. [PMID: 34116080 DOI: 10.1016/j.jhep.2021.05.035] [Reference Citation Analysis]
478 Kjær MB, George J, Kazankov K, Grønbæk H. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Rev Gastroenterol Hepatol 2021;15:51-64. [PMID: 32878486 DOI: 10.1080/17474124.2020.1817740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
479 Buchard B, Teilhet C, Abeywickrama Samarakoon N, Massoulier S, Joubert-Zakeyh J, Blouin C, Reynes C, Sabatier R, Biesse-Martin AS, Vasson MP, Abergel A, Demidem A. Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity. Metabolites 2021;11:54. [PMID: 33466889 DOI: 10.3390/metabo11010054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
480 Makri ES, Goulas A, Polyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 2021;907:174272. [PMID: 34147478 DOI: 10.1016/j.ejphar.2021.174272] [Reference Citation Analysis]
481 Wang XK, Peng ZG. Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease. Front Pharmacol 2021;12:655557. [PMID: 33935770 DOI: 10.3389/fphar.2021.655557] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
482 Fouda S, Khan A, Chan SMH, Mahzari A, Zhou X, Qin CX, Vlahos R, Ye JM. Exposure to cigarette smoke precipitates simple hepatosteatosis to NASH in high-fat diet fed mice by inducing oxidative stress. Clin Sci (Lond) 2021;135:2103-19. [PMID: 34427662 DOI: 10.1042/CS20210628] [Reference Citation Analysis]
483 Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34707258 DOI: 10.1038/s41575-021-00523-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
484 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-gomez M, Zelber-sagi S, Wai-sun Wong V, Dufour J, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-järvinen H, Fan J, Grønbæk H, Yilmaz Y, Cortez-pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M, Fouad Y, Chan W, Mendez-sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology 2020;73:202-9. [DOI: 10.1016/j.jhep.2020.03.039] [Cited by in Crossref: 390] [Cited by in F6Publishing: 420] [Article Influence: 195.0] [Reference Citation Analysis]
485 Zhou YJ, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40:2160-2163. [PMID: 32573883 DOI: 10.1111/liv.14575] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
486 Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: Deciphering communication from the liver. Mol Metab 2021;44:101138. [PMID: 33285302 DOI: 10.1016/j.molmet.2020.101138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
487 Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)00343-3. [PMID: 34090928 DOI: 10.1016/j.jhep.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
488 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Reference Citation Analysis]
489 Eslam M, Ratziu V, George J. Yet more evidence that MAFLD is more than a name change. Journal of Hepatology 2021;74:977-9. [DOI: 10.1016/j.jhep.2020.12.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
490 George J, Gish RG, Geier A. MAFLD and Cardiovascular Events: What Does the Evidence Show? Clinical Gastroenterology and Hepatology 2021;19:2025-8. [DOI: 10.1016/j.cgh.2021.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
491 Kunst RF, Niemeijer M, van der Laan LJW, Spee B, van de Graaf SFJ. From fatty hepatocytes to impaired bile flow: Matching model systems for liver biology and disease. Biochem Pharmacol 2020;180:114173. [PMID: 32717228 DOI: 10.1016/j.bcp.2020.114173] [Reference Citation Analysis]
492 Surlin P, Didilescu AC, Lazar L, Arsenie CC, Camen A, Popescu DM, Gheorghe DN, Osiac E, Rogoveanu I. Evaluation Through the Optical Coherence Tomography Analysis of the Influence of Non-Alcoholic Fatty Liver Disease on the Gingival Inflammation in Periodontal Patients. Diabetes Metab Syndr Obes 2021;14:2935-42. [PMID: 34234491 DOI: 10.2147/DMSO.S310314] [Reference Citation Analysis]
493 Maya-Miles D, Ampuero J, Gallego-Durán R, Dingianna P, Romero-Gómez M. Management of NAFLD patients with advanced fibrosis. Liver Int 2021;41 Suppl 1:95-104. [PMID: 34155801 DOI: 10.1111/liv.14847] [Reference Citation Analysis]
494 Hatasa M, Yoshida S, Takahashi H, Tanaka K, Kubotsu Y, Ohsugi Y, Katagiri T, Iwata T, Katagiri S. Relationship between NAFLD and Periodontal Disease from the View of Clinical and Basic Research, and Immunological Response. Int J Mol Sci 2021;22:3728. [PMID: 33918456 DOI: 10.3390/ijms22073728] [Reference Citation Analysis]
495 Liu Y. Reply to 'Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B'-A reply. J Viral Hepat 2021. [PMID: 34216526 DOI: 10.1111/jvh.13567] [Reference Citation Analysis]
496 Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. Front Med (Lausanne) 2020;7:616212. [PMID: 33392234 DOI: 10.3389/fmed.2020.616212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
497 Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502] [Reference Citation Analysis]
498 Abbate JM, Macrì F, Capparucci F, Iaria C, Briguglio G, Cicero L, Salvo A, Arfuso F, Ieni A, Piccione G, Lanteri G. Administration of Protein Hydrolysates from Anchovy (Engraulis Encrasicolus) Waste for Twelve Weeks Decreases Metabolic Dysfunction-Associated Fatty Liver Disease Severity in ApoE-/-Mice. Animals (Basel) 2020;10:E2303. [PMID: 33291840 DOI: 10.3390/ani10122303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
499 Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci 2021;22:4156. [PMID: 33923817 DOI: 10.3390/ijms22084156] [Reference Citation Analysis]
500 Sharma D, Gotlieb N, Farkouh ME, Patel K, Xu W, Bhat M. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. J Am Heart Assoc 2021;:e022576. [PMID: 34927450 DOI: 10.1161/JAHA.121.022576] [Reference Citation Analysis]
501 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
502 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
503 Chen BB, Yan JH, Zheng J, Peng HW, Cai XL, Pan XT, Li HQ, Hong QZ, Peng XE. Copy number variation in the CES1 gene and the risk of non-alcoholic fatty liver in a Chinese Han population. Sci Rep 2021;11:13984. [PMID: 34234263 DOI: 10.1038/s41598-021-93549-2] [Reference Citation Analysis]
504 Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2021;19:2138-2147.e10. [PMID: 33348045 DOI: 10.1016/j.cgh.2020.12.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
505 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
506 Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021;9:51-9. [PMID: 33604255 DOI: 10.14218/JCTH.2020.00057] [Reference Citation Analysis]
507 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
508 Wei JY, Xu Z, Li H, Du WQ, Niu BL, Li S, Tian S, Wu J, Chen YL, Li X, Liu ZL, Xiao J, Ren GS, Ran L, Kong LQ. Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China. Int J Med Sci 2021;18:3082-9. [PMID: 34400878 DOI: 10.7150/ijms.60780] [Reference Citation Analysis]
509 Deng D, George J, Pasupathy D, Wah Cheung N. The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population. Diabetes Res Clin Pract 2021;174:108757. [PMID: 33744378 DOI: 10.1016/j.diabres.2021.108757] [Reference Citation Analysis]
510 Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021;9:1491. [PMID: 34680608 DOI: 10.3390/biomedicines9101491] [Reference Citation Analysis]
511 Ampuero J, Aller R, Gallego-Durán R, Crespo J, Abad J, González-Rodríguez Á, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Martín-Mateos R, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernández-Guerra M, Augustín S, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. Liver Int 2021;41:2076-86. [PMID: 33896100 DOI: 10.1111/liv.14898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
512 Ribas V, de la Rosa LC, Robles D, Núñez S, Segalés P, Insausti-Urkia N, Solsona-Vilarrasa E, Fernández-Checa JC, García-Ruiz C. Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC. Cancers (Basel) 2021;13:4091. [PMID: 34439245 DOI: 10.3390/cancers13164091] [Reference Citation Analysis]
513 Ma Y, Sun K, Cao J, Qin X, Shi J, Li H, Zhang J, Zhang T. Acupuncture combined with Chinese herbal medicine on non-alcoholic fatty liver disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28083. [PMID: 34941049 DOI: 10.1097/MD.0000000000028083] [Reference Citation Analysis]
514 Kalyesubula M, Mopuri R, Asiku J, Rosov A, Yosefi S, Edery N, Bocobza S, Moallem U, Dvir H. High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition. Dis Model Mech 2021;14:dmm048355. [PMID: 33608323 DOI: 10.1242/dmm.048355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
515 Aykutlu U, Argon A, Orman M, Ulukaya S, Zeytunlu M, Karasu Z, Günşar F, Nart D, Akarca U, Yilmaz F. Steatotic and Steatohepatitic Hepatocellular Carcinomas: Features in a Series With Predominantly Viral Etiology. Am J Surg Pathol 2021;45:1252-63. [PMID: 33826548 DOI: 10.1097/PAS.0000000000001714] [Reference Citation Analysis]
516 Foschi FG, Conti F, Domenicali M, Giacomoni P, Borghi A, Bevilacqua V, Napoli L, Berardinelli D, Altini M, Cucchetti A, Ercolani G, Casadei-Gardini A, Bellentani S, Gastaldelli A, Tiribelli C, Bedogni G, Group BS. External Validation of Surrogate Indices of Fatty Liver in the General Population: the Bagnacavallo Study. J Clin Med 2021;10:520. [PMID: 33535679 DOI: 10.3390/jcm10030520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
517 Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E. Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. Liver Int 2021;41:1999-2008. [PMID: 34242466 DOI: 10.1111/liv.15013] [Reference Citation Analysis]
518 Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The Controversial Role of Human Gut Lachnospiraceae. Microorganisms 2020;8:E573. [PMID: 32326636 DOI: 10.3390/microorganisms8040573] [Cited by in Crossref: 104] [Cited by in F6Publishing: 108] [Article Influence: 52.0] [Reference Citation Analysis]
519 Mikolasevic I, Domislovic V, Turk Wensveen T, Delija B, Klapan M, Juric T, Lukic A, Mijic A, Skenderevic N, Puz P, Ostojic A, Krznaric Z, Radic-Kristo D, Filipec Kanizaj T, Stimac D. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. Eur J Intern Med 2020;82:68-75. [PMID: 32839076 DOI: 10.1016/j.ejim.2020.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
520 Lin SZ, Fan JG. Peripheral immune cells in NAFLD patients: A spyhole to disease progression. EBioMedicine 2021;75:103768. [PMID: 34929490 DOI: 10.1016/j.ebiom.2021.103768] [Reference Citation Analysis]
521 Hernández-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. J Clin Transl Hepatol 2021;9:227-38. [PMID: 34007805 DOI: 10.14218/JCTH.2020.00131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
522 Zaiou M, Amrani R, Rihn B, Hajri T. Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Biomedicines 2021;9:1256. [PMID: 34572442 DOI: 10.3390/biomedicines9091256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
523 Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time. Medicina (Kaunas) 2021;57:1057. [PMID: 34684094 DOI: 10.3390/medicina57101057] [Reference Citation Analysis]
524 Harjumäki R, Pridgeon CS, Ingelman-Sundberg M. CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. Int J Mol Sci 2021;22:8221. [PMID: 34360999 DOI: 10.3390/ijms22158221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
525 Meyersohn NM, Mayrhofer T, Corey KE, Bittner DO, Staziaki PV, Szilveszter B, Hallett T, Lu MT, Puchner SB, Simon TG, Foldyna B, Voora D, Ginsburg GS, Douglas PS, Hoffmann U, Ferencik M. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol 2021;19:1480-1488.e14. [PMID: 32707340 DOI: 10.1016/j.cgh.2020.07.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
526 Zhao J, Hu Y, Peng J. Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy. Cell Mol Biol Lett 2021;26:17. [PMID: 33962586 DOI: 10.1186/s11658-021-00254-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
527 Huang YP, Zhang S, Zhang M, Wang Y, Wang WH, Li J, Li C, Lin JN. Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study. BMJ Open 2021;11:e056260. [PMID: 34911725 DOI: 10.1136/bmjopen-2021-056260] [Reference Citation Analysis]
528 Molenaar MR, Penning LC, Helms JB. Playing Jekyll and Hyde-The Dual Role of Lipids in Fatty Liver Disease. Cells 2020;9:E2244. [PMID: 33036257 DOI: 10.3390/cells9102244] [Reference Citation Analysis]
529 Dawood RM, Salum GM, El-Meguid MA. The Impact of COVID-19 on Liver Injury: COVID-19 and Liver Injury. Am J Med Sci 2021:S0002-9629(21)00400-6. [PMID: 34752738 DOI: 10.1016/j.amjms.2021.11.001] [Reference Citation Analysis]
530 Eslam M, Wong GL, Hashem AM, Chan HL, Nielsen MJ, Leeming DJ, Chan AW, Chen Y, Duffin KL, Karsdal M, Schattenberg JM, George J, Wong VW. A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. Am J Gastroenterol 2021;116:984-93. [PMID: 33252454 DOI: 10.14309/ajg.0000000000001059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
531 Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
532 Chen B, Pan CQ. Non-Invasive Assessment of Fibrosis and Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. Clin Res Hepatol Gastroenterol 2021;:101755. [PMID: 34311134 DOI: 10.1016/j.clinre.2021.101755] [Reference Citation Analysis]
533 Brodosi L, Marchignoli F, Marchesini G, Petroni ML. Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opin Pharmacother 2021;:1-5. [PMID: 34541981 DOI: 10.1080/14656566.2021.1980538] [Reference Citation Analysis]
534 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Reference Citation Analysis]
535 Di Sessa A, Guarino S, Umano GR, Arenella M, Alfiero S, Quaranta G, Miraglia Del Giudice E, Marzuillo P. MAFLD in Obese Children: A Challenging Definition. Children (Basel) 2021;8:247. [PMID: 33806784 DOI: 10.3390/children8030247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
536 Wang Y, Tai YL, Zhao D, Zhang Y, Yan J, Kakiyama G, Wang X, Gurley EC, Liu J, Liu J, Liu J, Lai G, Hylemon PB, Pandak WM, Chen W, Zhou H. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. Cells 2021;10:210. [PMID: 33494295 DOI: 10.3390/cells10020210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]